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SYMPATHETIC INHIBITION ATTENUATES HYPOXIA INDUCED INSULIN 
RESISTANCE IN HEALTHY ADULT HUMANS 
 
 
Acute and chronic exposure to hypoxia is known to decrease insulin sensitivity in healthy 
humans and animals, while simultaneously increasing the activity of the sympathetic nervous 
system (SNS).  Likewise, obstructive sleep apnea (OSA) and chronic obstructive pulmonary 
disease (COPD) are clinical conditions characterized by hypoxia, elev t d SNS activity, and a 
high prevalence of insulin resistance.  In contrast to hypoxic exposure and hypoxic related
diseases, hyperoxia (FIO2 = 1.00) has been shown to improve insulin sensitivity while 
concomitantly decreasing SNS activity.  Consistent with this, continuous positive airway 
pressure (CPAP), a common OSA treatment, has proven effective in abolishing nocturnal bouts 
of intermittent hypoxia, enhancing insulin sensitivity and diminishing SNS activity.  Although 
the underlying mechanism of hypoxia induced insulin resistance remains unclear, it appears that 
elevated SNS activity may be a mediating factor.  Therefore, we hypothesized that inhibition of 
the SNS would attenuate hypoxia induced insulin resistance.  METHODS: 10 males (23±1 years, 
body mass index 24.2±0.8 kg/m2 (mean±SE)) reported to our laboratory on 4 separate mornings, 
separated by a minimum of 7 days,  after a 12-hour fast and 48-hour abstention from exercise. 
Insulin sensitivity was determined via the hyperinsulinemic euglycemic clamp technique under 
each of the following conditions: normoxia (FIO2=0.21), hypoxia (FIO2=0.11), normoxia and 
SNS inhibition (48-hour transdermal clonidine administration (Catapres-TTS; 0.2mg/day)), and 
hypoxia SNS inhibition.  RESULTS: Oxyhemoglobin saturation was decreased (P<0.01) during 
hypoxia (63±2%) compared to normoxia (96±0%) and there was no significant effect of SNS 
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inhibition on oxyhemoglobin saturation in either normoxia or hypoxia (P>0.25).  Norepinephrine 
was elevated in hypoxia (137±13%; P=0.02), as determined by area under curve and expressed 
relative to normoxia.  SNS inhibition prevented the hypoxia induced increase in norepinephrine 
(94±14%; P=0.43). The glucose infusion rate (adjusted for fat free mass and circulating insulin), 
required to maintain blood glucose at 90 mg/dl (5 mmol/L) during administration of insulin, was 
decreased during hypoxia (128±30 nmol/kg fat free mass/pmol/L/min; P=0.03) compared to 
normoxia (225±23) and remained unchanged during normoxia and SNS inhibition (219±19; 
P=0.86), and hypoxia and SNS inhibition (169±23; P=0.23).  CONCLUSION: Inhibition of the 
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Whole body glucose homeostasis is dependent on the rate of glucose appearance (Ra) and 
rate of glucose disappearance (Rd).   Ra is determined by glucose absorption from the intes ine 
and production by the liver and kidneys; whereas Rd is influenced by glucose uptake and 
metabolism by insulin-dependent tissues and insulin-independent tissues1,2.  Maintenance of 
glucose homeostasis is a balancing act achieved by alterations in Ra and Rd, with these processes 
being tightly regulated by pancreatic hormones and neuroendocrine signaling.  During times of 
hyperglycemia, such as the postprandial state,  insulin secretion (from pancreatic beta-cells) 
coupled with SNS withdrawal, decreases Ra by inhibiting hepatic glucose production and 
increases Rd by promoting insulin-dependent tissue glucose uptake, storage, and oxid tion2.  On 
the contrary, during times of hypoglycemia a combination of glucagon release (from pancreatic 
alpha-cells) and increased SNS activity promotes glucose Ra by stimulating hepatic glucose 
production and attenuates Rd by inhibiting peripheral glucose utilization3-8.    
Insulin, one of the primary glucoregulatory hormones, promotes glucose homeostasis 
through a series of successive steps that leads to the translocation of glucose transporter proteins 
(GLUT 4) to the plasma membrane and subsequent glucose uptake9.  Primarily found  in muscle 
and adipose tissues, GLUT 4 accounts for a majority of whole body, insulin mediated glucose 
disposal10.  GLUT 4 facilitates the cellular uptake of glucose from circulation for oxidation 
and/or glycogen storage.  Cellular oxidation of glucose results in the production of reducing 
equivalents and adenosine tri-phosphate that can be utilized as an energy source.  Glucose can 
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also be stored as glycogen through a process known as glycogenesis that occurs predominantly in 
muscle and the liver1,2,11.   
 Unfavorable perturbations to either the insulin signaling cascade or GLUT 4 
translocation can result in dysregulation of glucose homeostasis and insulin reistance.  Insulin 
resistance is a clinical condition where elevated levels of plasma insulin coincide with higher 
than normal plasma glucose levels12,13.  Most commonly, insulin resistance is associated with 
type 2 diabetes mellitus (T2DM) that is known to have profound metabolic consequences.  There 
are several known factors that can promote the development of insulin resistance such as visceral 
adiposity, high-fat diets, and inactivity.  Additionally, exposure to hypoxia has also been shown 
to induce insulin resistance.  Healthy, adult humans and animals exposed to acute, chronic or 
intermittent hypoxia, each demonstrate a reduction in insulin sensitivity3,14-16.  This effect has 
been replicated under a variety of low oxygen conditions including: high altitude exposure16, 
hypoxic gas breathing3, and hypobaric hypoxia15.  In addition to inducing insulin resistance, 
hypoxia has also been associated with increased SNS activity3,17.  However, exposure to 
hyperoxia (FIO2=1.00), has been shown to have the opposite effect; increasing insulin sensitivity 
while concomitantly decreasing SNS activity18.   
In parallel, diseases of hypoxia, such as obstructive sleep apnea (OSA) and chronic 
obstructive pulmonary disease (COPD), have high prevalence of insulin resistance.  OSA  is a 
disease distinguished by momentary cessations of breathing (apneas) or decreases in breath 
amplitude (hypopneas), caused by a compromised upper airway and a decrease in brain stem 
respiratory motor output,  sufficient enough to induce hypoxemia during sleep19,20.  Likewise, 
COPD is classified as a hypoxic respiratory disease exemplified by air-flow obstruction resulting 
from chronic inflammation of the airways due to long-term inhalation of tobacco smoke, noxious 
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gases, or fine particulates21.  Despite having slightly different pathologies, OSA and COPD share 
several of the same attributes including: arterial oxygen desaturation (characteristic of hypoxia), 
elevated SNS activity, and a reduction in insulin sensitivity22-28.  Treatments aimed at 
ameliorating the hypoxic exposure characteristic of both these disease have proven effective29,30.  
Concurrent with eliminating hypoxic exposure, these treatments have favorable effects on insulin 
sensitivity and SNS activity.  Specifically, CPAP, a common OSA treatm n , has been effective 
in abolishing nocturnal bouts of intermittent hypoxia, enhancing insulin sensitivity, and reducing 
SNS activity29, while oxygen supplementation in COPD patients has been shown to have similar 
effects30.  
Although the underlying mechanism of hypoxia induced insulin resistance remains 
unclear, the aforementioned evidence suggests elevated SNS activity may bea mediator3.  The 
potential mechanism by which elevated SNS activity could mediate hypoxia induced insulin 
resistance is through the actions of epinephrine and norepinephrine.  Epinephrine and 
norepinephrine are catecholamines found in systemic circulation; with elevated levels being 
indirectly associated with increased SNS activity.  Epinephrine has been shown to promote 
glycogenolysis while concurrently inhibiting glucose uptake, oxidation, and storage3-7.   
Norepinephrine acts in concert with epinephrine to increase lipolysis6,31.  Plasma lipids interfere 
with insulin stimulated glucose uptake, leading to a decrease in insulin sensitivity31,32.  
Therefore, targeting the sympathetic nervous system appears to be a potentially viable solution 
for the treatment of hypoxia induced insulin resistance.   
Due to the complexities of human physiology, it appears unlikely, that elevated 
sympathetic nervous system activity is exclusively responsible for hypoxia induced insulin 
resistance.  Therefore, it is important to consider other known circulating insulin sensitizing and 
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desensitizing factors that are regulated by hypoxia.  Specific insulin (de)sensitizing that are 
regulated by hypoxia  include but are not limited to: adiponectin33, pigment epithelium derived 
factor34, oxidized low density lipoproteins35, tumor necrosis factor-alpha36, and non-esterified 
fatty acids37.  All have the potential to contribute to hypoxia induced insulin resistance. 
There are several practical implications of identifying the mechanism(s) that underlies 
hypoxia induced insulin resistance.  Clinically, effective treatment options for hypoxia related 
diseases have the potential to reduce the prevalence or development of insulin resi ta ce.  
Effective treatments aimed at hypoxia will have many positive downstream effects, such as 
reducing medical costs and increasing quality of life.  Additionally, there ar m ny healthy 
individuals exposed to hypoxia on a regular basis, ranging from those who voluntarily flock to 
high altitude ski villages and mountain locales to recreate or soldiers that are expos d to on the 
job altitude extremes.  These individuals may also benefit from effective hypoxia therapies that 
decrease the negative effects of high altitude exposure and have the potential t improve 
performance.  Therefore, we sought to investigate whether inhibition of the sympathetic nervous 
system will attenuate hypoxia induced insulin resistance. 
 
Statement of Problem 
 Individuals diagnosed with OSA and COPD are regularly exposed to hypoxia that elicits 
arterial oxygen desaturation.  Additionally, OSA and COPD elevate basal SNS activity nd 
reduced insulin sensitivity.  Likewise, healthy individuals exposed to hypoxia also demonstrate 
elevated SNS activity and reduced insulin sensitivity.  Despite this knowledge, the mechanism 
mediating hypoxia induced insulin resistance remains unclear.  Therefore, we hope to elucidate 
whether elevated SNS activity and/or other circulating insulin (de)sensitizi g factors are 
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mediating this effect.  Identification of a mechanism will have clinical implication for individuals 
with hypoxia related disorders.   
 
Hypothesis and Specific Aims 
 We hypothesized that inhibition of the sympathetic nervous system would attenuate 
hypoxia induced insulin resistance.  Accordingly, we developed the following specific aim: to 
determine, in a random order, insulin sensitivity via the hyperinsulinemic euglycmic lamp 
technique during four conditions: normoxia (FIO2=0.21), hypoxia (FIO2=0.11), normoxia and 
SNS inhibition (48-hour transdermal clonidine administration (Catapres-TTS; 0.2mg/day)), and 
hypoxia and SNS inhibition.   
Additionally, it appears unlikely that elevated SNS activity is exclusively responsible for 
hypoxia induced insulin resistance.  Therefore, we sought to gain insight into whether other 
known circulating insulin sensitizing and desensitizing factors are regulat d by hypoxia 
including: adiponectin, pigment epithelium derived factor, oxidized low density lipoproteins, 







 The insulin signaling pathway is of pivotal importance for the maintenance of whole 
body glucose homeostasis.  Insulin is one of the primary hormones responsible for initiation of 
the insulin signaling cascade, that leads to the partial regulation of Ra and Rd through various 
intermediates9.  Insulin receptors are found on nearly all vertebrate cells in varying de sities;  
ranging from 40 – 200,000 receptors on a single cell9.  The receptor is a large trans-membrane 
protein, 300-400 kDa in size, comprised of two alpha and two beta-subunits38.  The two alpha-
subunits, located on the extracellular surface of the cell, serve as the insulin binding domain 
while the beta-subunits, located on the intracellular surface of the cell, contain the insulin 
regulated tyrosine protein kinase9.   
When insulin is not present, the unbound extracellular alpha-subunits inhibit the intrinsic 
intracellular tyrosine kinase activity of the beta-subunits.  However, when insulin binds to one of 
the alpha-subunits, this inhibition is removed, and the adjacent intracellular beta-su unit is 
autophosphorylated at its tyrosine residues of the regulatory domain39.  Subsequently, 
autophosphorylation allows the insulin receptor to activate, via tyrosine phosphorylation, a 
variety of intracellular insulin receptor substrate proteins (IRS)38,40-43.  These IRS proteins act as 
insulin receptor specific docking proteins that create recognition sites for additional effector 
molecules with Src homology 2 (SH2) domains, such as the p85 regulatory subunit of the type 
1A phosphatidylinositol 3–kinase (PI(3)K)2,38.  These IRS docking proteins serve multiple 
functions.  They have the ability to amplify the insulin receptor signal, dissociate the intracellular 
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signaling cascade with the membrane bound insulin receptor, expand the number of pathways 
that can be regulated through one insulin receptor, and serve as a common substrate for multiple 
receptors, allowing the integration of multiple metabolic signals40,44. 
The insulin signaling cascade encompasses 40 known downstream intermediates45 th t 
involves three primary pathways: the PI(3)K/Akt pathway, the Cbl/CAP pathway, and the 
mitogen activated protein kinase (MAPK) cascade2.  The PI(3)K pathway appears to play the 
biggest role in the maintenance of whole body glucose homeostasis.  However, the MAPK and 
Cbl/CAP pathways are also of integral importance for the maintenance of glucose homeostasis.  
 PI(3)K plays a significant role in many of the metabolic processes a sociated with insulin 
including: glucose uptake, growth, protein synthesis, and glycogen synthesis40.  Insulin 
stimulates glucose uptake via the PI(3)K pathway through multiple steps including: activation of 
IRS by the insulin receptor, binding of IRS to the PI(3)K regulatory subunit p8546,47, 
phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) leading to increased 
concentrations of phoshphatidlyinositol 3,4,5-trisphosphate (PIP3), activation of atypical protein 
kinase C (aPKC) and Akt through phosphoinositide-dependent kinase-1(PDK1), and GLUT 4 
translocation to the plasma membrane for facilitation in cellular glucose uptake 48,49.  The 
activation of both aPKC and Akt has been shown to be required for the translocation of GLUT 4 
to the plasma membrane49-51.  Therefore, it is not surprising that insulin resistance is often 
associated with dysregulation of aPKC and Akt activation49.  The dysregulation of aPKC and 
Akt in insulin resistance is supported by evidence from embryonic stem cell aPKC knockouts 
and adipocyte  aPKC knockouts that demonstrate impaired insulin stimulated glucose uptake52.  
Likewise, Akt2 deficient mice have also been shown to become insulin resistant as a result of 
attenuated GLUT 4 translocation53.   
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   In addition to the PI(3)K/Akt pathway, the mitogen activated protein kinase (MAPK) 
cascade plays a substantive role in the maintenance of glucose homeostasis.  Insulin stimulates 
MAPK activity by activating GTP-binding proteins (G-proteins) that transduce the signal 
through a complex series of kinase tiers54.  There are four main variants of the MAPK signaling 
cascade that arise as the signal navigates through these kinase tiers that ncluding: ERK, JNK, 
p38, and BMK signaling pathways54.  The ERK cascade has been implicated in the regulation of 
insulin sensitivity through transcriptional control of the insulin-like receptor gene, “pointed”55.  
Similarly, activation of the p38 pathway has been shown to positively affect insulin sensitivity 
through insulin mediated glucose uptake but not through contraction mediated glucose uptake56, 
while BMK has been shown to be attenuated with insulin resistance57.  Contrary to the positive 
effects of the ERK, p38, and BMK pathways; the JNK pathway is elevated in obesity, while 
ablation of JNK1 mediates an increase in insulin sensitivity58.  Thus, the MAPK signaling 
cascade can have a range of effects on glucose homeostasis.   
In addition to the PI(3)K and MAPK pathways, the Cbl/CAP pathway also contributes to 
the maintenance of glucose homeostasis59,60.  The Cbl/CAP pathway is mediated by two adaptor 
molecules known as CAP and APS; with Cbl and CAP forming the Cbl/CAP complex61.  The 
insulin receptor activates APS, APS recruits cytoplasmic Cbl/CAP to the insulin receptor, Cbl is 
phosphorylated, the Cbl/CAP complex relocates to the caveolin-enriched lipid rafts of the plasma 
membrane, the CAP protein interacts with the lipid raft62 leading to the recruitment of the 
Crk/C3G complex, C3G activates TC10, and GLUT 4 is translocated to the plasma me brane 
for the facilitation of cellular glucose uptake63.  Evidence for the role of the Cbl/CAP pathway in 
the maintenance of glucose homeostasis comes from an obese mouse model.  This obese mouse 
model has suggested that the decrease in insulin sensitivity associated with excess adiposity is 
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partially due to the down regulation of the Cbl/CAP pathway64.   Like the previous pathways 
there is direct link between activation of the Cbl/CAP pathway and cellular glucose uptake, with 
evidence to support this.  A summary of insulin signal transduction can be found in Figure 1. 
The insulin receptor also has the important task of degrading insulin.  After insulin has 
bound the insulin receptor, the receptor and substrate undergo endocytosis9,65-67.  Upon 
internalization, insulin is cleaved from the insulin receptor and degraded by a prote se while the 
unbound insulin receptor is either degraded  or recycled back to the plasma membrane9,68.  
Traditionally, endocytosis has been thought of as a degradation pathway, however it is also 
acknowledged that endocytosis may be necessary for intracellular propagation of insulin 
action69,70.  Either way, this process occurs rather frequently  indicative of the relatively short, 30 
minute half-life of insulin; whereas the insulin receptor is often recycled, giving it a longer half-
life of  approximately 10 hours71,72.  Interestingly, the half-life of the insulin receptor tends to 
decline during prolonged insulin exposure through the increased activity of endocytotic 
lysosomal degradation53,73.  Decreased insulin receptor concentrations have been associated with 
an attenuated  tissue responsiveness to insulin and  have been shown to contribute to the 
pathogenesis of insulin resistance70.  
Additionally, serine phosphorylation and protein tyrosine phosphatases (PTP’s) have 
been shown to attenuate insulin signaling.  Specifically, serine phosphorylation disrupts nsulin 
signaling through the inhibition of tyrosine phosphorylation by fostering interactions with 14-3-3 
proteins74,75.  Likewise, PTP’s can interfere with the tyrosine phosphorylation cascade essential 





GLUT 4 Proteins  
The primary objective of the insulin signaling cascade, for the purposes of whole body 
glucose homeostasis, is to promote facilitative cellular glucose uptake through the translocation 
of GLUT 4 proteins to the plasma membrane.  GLUT 4 proteins, predominantly found in muscle
tissue account for a majority of whole body, insulin mediated glucose disposal.  The importance 
of GLUT 4 is evident by the fact that: insulin-mediated glucose uptake (GLUT 4) is the rate 
limiting step for glucose absorption in muscle and adipose10, h terozygous GLUT 4 knockout 
mice become insulin resistance70, GLUT 4 translocation to the plasma membrane is severely 
disrupted in insulin resistance and T2DM77, inadequate GLUT 4 recruitment – despite adequate 
expression – is associated with insulin resistance66, and GLUT 4 over expression in diabetic mice 
(db/db)  attenuates insulin resistance65.   
 Despite the importance of GLUT 4 in the regulation of whole body glucose homeostasis, 
the exact mechanisms of the insulin mediated GLUT 4 translocation pathway and the 
intracellular sequestering locations of GLUT 4 remain elusive.  Similarly, there has yet to be 
complete convergence between the insulin signaling pathway and subsequent activation of 
GLUT 4 translocation.  The GLUT 4 protein itself can be found in many organelles of the cell 
including: the plasma membrane, sorting endosomes, recycling endosomes, the trans-Golgi 
network (TGN), and transport vesicles10. Compared to other common constitutively exocytosed 
proteins, the rate of non-insulin stimulated GLUT 4 exocytosis is much slower, indicating that  
GLUT 4 exocytosis must be restrained in some manner10.  It is thought that GLUT 4 is either 
retained in an intracellular location, compartmentalized in vesicles that remin static in the 
absence of stimulation, involved in a dynamic intracellular transport loop that circumnavigates 
recycling endosomal vesicles, or a combination “multiple pools” of the three10,46.  In support of 
11 
 
the “multiple pools” hypothesis, it has been demonstrated that under basal conditions only a 
portion, approximately 30 - 40%, of GLUT 4 proteins are localized to recycling endosomes67 as 
GLUT 4 translocation occurs despite chemical ablation of these endosomes47. There is also 
evidence to support a dynamic transport loop between GLUT 4 containing endosomes and the 
TGN.  When GLUT 4 is tracked upon endocytosis from the plasma membrane of adipocytes, it 
tends to localize in the vicinity of the TGN74.  Similarly, when adipocytes are incubated 19° 
Celsius, the temperature that inhibits export from the TGN, insulin action is inhibited10,75.  
Additionally, in response to insulin, GLUT 4 is not only localized to the plasma membrane y 
TGN sorting, but also by small GLUT 4 containing vesicles.  These special GLUT 4 
sequestering vesicles are recognized by the presence of VAMP2, a docking and fusing protein 
that enables GLUT 4 to be incorporated into the plasma membrane78.  Based upon this evidence, 
it appears that GLUT 4 proteins are sequestered in “multiple pools” awaiting the proper signal 
for translocation to the plasma membrane. 
  Although the insulin signal serves as a potent activator of GLUT 4 translocation to the 
plasma membrane, there are three unique PIP3 phosphatases, PTEN, SHIP2, and SKIP, that each 
play a role in attenuating Akt activation and inhibition of GLUT 4 translocation79.  PTEN over 
expression has been shown to inhibit GLUT 4 translocation and glucose uptake, while PTEN and 
SKIP knockout mice demonstrate insulin hypersensitivity10,51,77.  Similarly, the phosphatase 
SHIP2 has also been shown to attenuate insulin stimulated glucose uptake 50.  Although each of 
these phosphatases negatively influence insulin sensitivity through inhibition of GLUT 4 
translocation, SKIP plays the predominant role79.   
In addition to GLUT 4 being regulated prior to or during translocation, it can also be 
regulated after translocation.  Glucose transporter activity, at the membrane, has been shown to 
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be altered by phosphorylation76, nucleotide binding80 and through variations in its oligomeric 
structure81.  Analogously, the location of GLUT 4 within the membrane may also alter its ability 
to transport glucose as the receptor has been detected in both clathrin coated pits and the 
caveolae of the plasma membranes10,82,83.  Ultimately, there are various points throughout the 
insulin signaling cascade and translocation of GLUT 4  that glucose uptake can be regulated. 
 
Insulin Resistance 
The potency of insulin to promote peripheral insulin dependent tissue glucose uptake is 
termed insulin sensitivity.  Insulin sensitivity describes the effectiveness of insulin to stimulate 
the removal of glucose from plasma and subsequent uptake into myocytes, adipocytes, or 
hepatocytes for oxidation or storage84.  Alternatively, a poor degree of insulin sensitivity is 
termed insulin resistance.  Insulin resistance is characterized by elevated levels of plasma insulin 
results in higher than normal plasma glucose levels12,13.  The development of insulin resistance 
initially leads to compensatory hyperinsulinemia.  This is maintained, often for years, until 
dysfunction of pancreatic beta-cells results in an inability to compensate for p ripheral tissue 
(muscle, adipose, and liver) insulin resistance – unable to produce enough insulin – and 
hyperglycemia manifests12. 
The first stage of hyperglycemia is known as pre-diabetes.  For healthy individuals, 
normal fasting (12 hour fast) plasma glucose levels are less than 100 mg/dl (5.6 mmol/l), 
whereas pre-diabetes fasting plasma glucose concentrations range from 100–125 mg/dl (5.6–6.9 
mmol/l).  Comparably, a normal blood glucose level, two hour post an oral glucose tolerance test 
(ingestion of 75 grams of dissolved anhydrous glucose in water) is less than 140 mg/dl (7.8 
mmol/l), while in pre-diabetes it ranges from 140–199 mg/dl (7.8–11.1 mmol/l)85.  If pre-diabetic 
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hyperglycemia is exacerbated, by additional peripheral insulin resistance, pancreatic beta-cell 
dysfunction, and/or increased hepatic gluconeogenesis, the consequence is T2DM12,86.  
Clinically, the diagnostic criteria for the development of T2DM includes:  a fasting plasma 
glucose level >126 mg/dl, or symptoms of diabetes and a casual plasma glucose concentration of 
>200 mg/dl or a plasma glucose concentration of >200 mg/dl two hours post an oral glucose
tolerance test.  After one positive test, a second test on a different day is often needed to confirm 
the diagnosis85.  Likewise,  individuals with undiagnosed T2DM may have a variety of 
symptoms including: frequent urination, extreme thirst, unusual hunger, fatigue, irritabil ty, 
frequent infections, blurred vision, wounds and bruises that are slow to heal, tingling and 
numbness in the hands and feet, and recurring skin, gum, and bladder infections87.   It is 
important to note that pre-diabetes, in and of itself, is not a diagnosis of T2DM but merely a risk 
factor for future development of the disease.   
According to the 2011 Diabetes National Fact Sheet, 8.3% of the population or 25.8 
million United States citizens are afflicted with diabetes, with another 79 million people being 
classified as pre-diabetic88. It has been estimated that for individuals born in the year 2000 the 
life-time risk of developing diabetes (predominantly T2DM) is as follows: 32.8% for Caucasian 
males, 38.5% for Caucasian females, 45.4% for Hispanic males, and 52.5% for Hispanic 
females89.  This is important for several reasons: individuals diagnosed at the age of forty will 
lose approximately 13 life-years and  20 quality-of-life adjusted years89 nd  have twice the risk 
of dying versus individuals the same age without diabetes88.  In 2006, diabetes was the seventh 
leading cause of death and is associated with: heart disease, stroke, high blood pressure, 
blindness, kidney disease, neuropathy, and amputation.  It is the leading cause of new cases of
blindness and kidney failure.   
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Not only is T2DM detrimental to health but the economic costs associated with the 
disease are astronomical.  It has been estimated that in 2010 the cost associated with diabetes 
was approximately $174 billion dollars, excluding the cost of the 79 million individuals who 
have pre-diabetes87.  Thus, the development of successful preventative and treatment options for 
this devastating disease of insulin resistance should improve quality of life, decr as  mortality, 
and drastically reduce associated medical costs. 
 
Hypoxia Induced Insulin Resistance 
The acute and chronic effects of exposure to conditions of low oxygen have been 
thoroughly documented in both animal and human models.  It has been demonstrated in both 
models that low oxygen environments can induce insulin resistance that is characteristic of 
T2DM.  In newborn calves, two hours of hypoxic exposure have been shown to increase levels 
of circulating glucose and insulin90.  Likewise, in rats, seven days of hypoxic exposure results in 
increased levels of plasma insulin with no change in plasma glucose91, while in obese mice, 
long-term (12 weeks) exposure to intermittent hypoxia leads to an increase in serum insulin and 
decrease in glucose tolerance, indicative of insulin resistance14.  Equally, in humans acute and 
chronic hypoxic exposure has been shown to attenuate insulin sensitivity independent of 
sex3,15,16.  Therefore, it appears that hypoxia can induce a phenotype of insulin resistance similar 
to that of pre-diabetes or T2DM.    
It was not until the early 1990’s that the study of glucose homeostasis in response to 
acute and chronic hypoxia in humans began to gain momentum.  Initially, it was postulated hat 
insulin sensitivity was improved in response to acute and chronic hypoxia while others beli ved 
the opposite to be true.  In one study, examining glucose kinetics during a stay at 4300 meters, 
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with stable isotope infusion, it was determined that chronic altitude exposure improves insulin 
sensitivity during energy balance92.  This was based on the determination that chronic altitude 
decreased fasting plasma glucose concentrations by14%, while both glucose Ra and Rd doubled 
compared to sea-level values despite there being no difference in plasma insulin concentrations.  
Additionally, chronic altitude was associated with a 153% increase in epinephrine and 136% 
increase in norepinephrine compared to sea-level values92. 
It appears, based upon this data, that chronic altitude improves insulin sensitivity.  
Despite unchanging insulin concentrations there was a decrease in fasting plasma g ucose values, 
while Rd increased drastically compared to sea-level values.  Both are indicative of improved 
insulin action92.  However, it is important to note that in this study, insulin sensitivity was not 
measured directly via the euglycemic hyperinsulinemic clamp technique, often considered to be 
the gold-standard of measuring insulin sensitivity93.  Instead, insulin action was derived from 
plasma glucose concentrations, glucose Ra and Rd, and levels of circulating insuli .   
Around the same time period, another group showed the insulin desensitizing effects 
chronic hypoxic exposure to varying altitude.  In this study, a group of 15 healthy men were 
studied at sea-level, transferred to 3500 meters for a 4 week stay, followed by a stay at 5080 
meters for additional 2 weeks94.  Upon exposure to 3500 meters there was an increase in fasting 
blood glucose and insulin concentrations on day 3, with insulin levels remaining elevated on day 
7 of exposure, compared to sea-level values94.  Likewise, with increasing altitude severity (5080 
meters), there was an increase in plasma glucose concentrations, that was apparent for 41 days, 
while insulin levels remained similar to that of exposure to 3500 meters94.  These data, contrary 
to the aforementioned glucose kinetics study, suggest that hypoxia exposure induces i s lin 
resistance as evident by elevated plasma glucose concentrations in spite of elevated plasma 
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insulin concentrations.  Ultimately, the results of these two similar, yet conflicting, altitude 
studies paved the way for future investigations into the effects of hypoxia on glucose 
homeostasis. 
With these prior altitude studies in mind, another group set out to directly test the ffects 
of altitude acclimatization upon glucose homeostasis.  In order to address altitude acclimatization 
upon glucose homeostasis, eight healthy men were examined on three different occasions: sea 
level, day 2 of altitude exposure (4559 meters), and day 7 of altitude exposure (4559 meters)16.  
During these three separate occasions, measures of insulin sensitivity were carried out via the 
two-step hyperinsulinemic euglycemic clamp technique.  Upon comparison of gluc se infusion 
rates across the three different time points, it was determined that insulin stimulated glucose 
uptake was reduced by half during day 2 of altitude exposure (4.5±0.6 mg/kg/min), compared to 
sea-level (9.8±1.1), while it was partially restored by day 7 of altitude exposure (7.4±1.4)16.  
Meanwhile, hepatic insulin sensitivity remained unchanged across all conditions16.   The largest 
reduction in glucose tolerance was found during day 2 which coincided with peak acute 
mountain sickness values16.  This decrease in insulin sensitivity, on day 2, was rationalized to 
result from a significant increase in cortisol and norepinephrine during the same time period.  
Subsequent partial recovery of insulin sensitivity on day 7 was attributed to decreasing cortisol 
concentrations that returned to sea-level values and chronic elevated norepinephrine xposure 
throughout the stay at altitude.  The partial recovery of insulin sensitivity as a result of 
decreasing cortisol concentrations is line with previous research that has  implicated cortisol in 
induction of insulin resistance95 through its role in decreasing the activity of glycogen synthase 
in skeletal muscle96.  Likewise, norepinephrine had been shown to acutely decrease insulin 
sensitivity97 while chronic norepinephrine exposure, such as day 7 of altitude exposure,  has been 
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demonstrated to illicit an increase in insulin sensitivity98.  In essence, this was the first study to 
directly demonstrate that hypoxia induces insulin resistance in man. 
 Despite the characterization of the effects of chronic (2-7 days) altitude exposure and 
glucose homeostasis in men, little was known about the acute effects of altitude exposur  on 
glucose homeostasis.  To answer this question, a group of researchers sought to determine if 
dysregulation of glucose homeostasis occurs in healthy individuals exposed to acute, normobaric 
hypoxia3.  In a double-blind, within subject, cross-over design study, fourteen healthy males 
were exposed to either normoxia or a brief 30 minute (acute exposure) bout of hypoxia as insulin 
sensitivity was  measured with the hyperinsulinemic euglycemic clamp technique.  The severity 
of hypoxia introduced during the hypoxic intervention was sufficient to decrease arterial oxygen 
saturation from 96% to 75%.  It was determined that hypoxia, compared to normoxia, induced a 
significant decrease in glucose infusion rates; that gradually began after administration of 
hypoxia, reached its peak 20 minutes after hypoxic exposure ended, and did not improve for 150 
minutes after cessation of hypoxic exposure.  Additionally, there was evidence of i reased SNS 
activity (elevated plasma epinephrine concentrations) that coincided with the hypoxia induced 
insulin resistance.   
Subsequently, to determine if the hypoxic exposure itself caused the observed decrease in 
glucose tolerance or if the hypoxia induced rise in epinephrine caused the glucose intolerance, a 
non-specific control was performed3.  For the non-specific control, glucose infusion rates were 
compared during conditions of hypoxia to that of hypoglycemia. Previously, it had been shown 
that hypoglycemic induced insulin resistance is due to elevated SNS activity and is reversible 
through beta-adrenergic receptor antagonism99.   Therefore, if SNS activity is greater during 
conditions of hypoglycemia compared to hypoxia, and epinephrine is the sole mediator of the 
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observed hypoxia induced insulin resistance, there should be increased insulin resistace during 
hypoglycemia compared to hypoxia.  Despite there being significantly greater concentrations of 
plasma catecholamines in the hypoglycemic group, both groups displayed similar levels of 
glucose intolerance.  Therefore, this suggested that the decrease in glucose tolerance associated 
with acute hypoxia is only partially mediated by increased epinephrine levels3.  Aside from 
epinephrine, other mechanisms mediating glucose intolerance were proposed, such as ATP-
sensitive potassium (K+) channels that are found in both skeletal muscle and the medio-basal 
hypothalamus.  K+ channels have been shown to act in concordance with epinephrine to decrease 
skeletal muscle glucose uptake and increase hepatic glucose output and could potentially explain 
the decrease in insulin sensitivity observed100,101.  Another possibility is that hypoxia could have 
raised plasma catecholamines enough to reach Kmax, resulting in no further decline in insulin 
sensitivity despite an even greater concentration of plasma catecholamines.  E ther way, this 
study was the first to suggest that acute hypoxia induces insulin resistance th t is, at least in part, 
mediated through an increase in plasma catecholamines.  
 In addition to acute and chronic hypoxia having the ability to attenuate insulin sensitivity, 
intermittent hypoxia has been shown to have a similar effect102.  In a study that examined the 
consequences of intermittent hypoxia, healthy individuals were blindly exposed to short, 
repeated bouts of hypoxia over the course of eight hours.  Each individual was subject to 24 
hypoxic events per hour, with each event lasting long enough to significantly decreas  arterial 
oxygen saturation102.  During the final three hours, of the eight hour trial, subjects were 
administered an intravenous glucose tolerance test (IVGTT).  From the IVGTT and additional 
blood sampling, it was determined that intermittent hypoxia induced a 17% decrease in insulin 
sensitivity that was associated with an increase in sympathetic nervous system activity102. 
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  The majority of studies have investigated hypoxia induced insulin resistance specifically 
in males.  The reason, often cited, for excluding females in such studies is that the ormonal 
fluctuations stemming from their menstrual cycle confounds the result of the study with 
additional variables.  Despite the potential confounding variables of researching females, a study 
was conducted that shows similar levels of glucose intolerance in females exposed to conditions 
of low oxygen as compared to males15.  In this investigation, twelve healthy females were 
subject to 68 hours of normobaric hypoxia, followed immediately by 52 hours of hypobaric 
hypoxia; once with and once without alpha-1-adrenergic receptor antagonism.  After 16 hours of 
either normobaric or hypobaric hypoxia, with and without alpha-1-adrenergic receptor 
antagonism, insulin sensitivity was determined by the Homeostatic Model Assssment-Insulin 
Resistance (HOMA-IR) and the Composite Model Insulin Sensitivity Index (C-ISI), while 
pancreatic beta cell function was determined by the Homeostatic Model Assessment-Beta Cell 
Function (HOMA-BCF)15.  Both measures have been shown to correlate well with euglycemic 
and hyperglycemic clamp techniques103. Based upon these measures, it was established that acute 
hypobaric hypoxia induces insulin resistance and decreases insulin sensitivity, with alpha-1-
adrenergic antagonism having no effect on insulin sensitivity during hypobaria.    Furthermore, 
hypobaria was shown to elevate plasma epinephrine concentrations, compared to normobaric 
conditions15.  Despite the concurrent decrease in insulin sensitivity and rise in epinephrine 
concentrations, it was concluded that epinephrine was not mediating the decrease in insulin 
sensitivity as alpha-1-adrenergic antagonism had no effect on insulin sensitivity15.  However, 
alpha-1-adrenergic receptor antagonism is unlikely to influence sympathetic stimulation of 
glycogenolysis, hepatic glucose production, or inhibition of insulin release as these are primarily 
beta-adrenergic receptor and alpha-2-adrenergic mediated functions104,105.  Therefore, these 
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results reinforce the findings of other studies conducted in men, indicating that hypoxic exposure 
induces a decrease in insulin sensitivity in females that may be mediated by increased 
sympathetic nerve activity.    
Both acute and chronic hypoxic exposure attenuates insulin sensitivity.  Thus, the 
question arises as to whether hyperoxia may have the opposite effect on insulin sensitivity.  
There is evidence that suggests hyperoxia will improve insulin sensitivity.  This is based upon 
how the carotid body, a peripheral chemoreceptor, responds to varying arterial oxygen 
saturation.  The carotid bodies are responsible for the activation of sensory afferent neurons as a 
result of a hypoxia induced decrease in arterial oxygen saturation106.  Subsequently, there is 
increased sympathetic outflow, due to carotid body activation, that increases c rdiac output in an 
attempt to maintain tissue oxygen delivery despite decreased arterial oxygen saturation.  
Likewise, hypoglycemia can mediate the same afferent carotid body respons  that is present in 
low oxygen environments,  increasing sympathetic outflow107,108 and inducing insulin 
resistance109. 
If insulin desensitization is mediated by increased sympathetic outflow that is ultimately 
controlled by the carotid bodies, it is reasonable to see why there is insulin desensitization under 
conditions of either hypoxia or hypoglycemia3.  Likewise, if hyperoxic exposure desensitizes the 
carotid bodies then it would be expected that under conditions of hyperoxic hypoglycemia, 
sympathetic outflow would be reduced and there would be an attenuation of hypoglycemic 
induced insulin resistance.  To investigate the effects of hyperoxia on insulin dependent glucose 
uptake, insulin sensitivity was determined via the hyperinsulinemic euglycemic lamp technique 
in seven healthy adults under conditions of normoxic hypoglycemia (FIO2=0.21; 60 mg/dl or 3.3 
mmol/l) and hyperoxic hypoglycemia (FIO2=1.00; 60 mg/dl or 3.3 mmol/l)
110.  Insulin sensitivity 
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was found to be 44.2% greater during hyperoxic hypoglycemia compared to normoxic 
hypoglycemia110.  In addition, the areas under the epinephrine and norepinephrine curves were 
decreased 62.6% and 50.7% during hyperoxic hypoglycemia compared to normoxic 
hypoglycemia110.  The finding that hyperoxia improves insulin sensitivity and decreases plasma 
catecholamines are consistent with the idea that hyperoxia suppresses hypoglycemic carotid 
chemoreceptor activation, preventing the hypoglycemic induced increase in SNS activity and 
rescuing insulin sensitivity.  Therefore, it appears that low oxygen environments stimulate 
carotid body afferent activity, increase sympathetic outflow, and induce insulin resistance.  On 
the other hand, hyperoxic environments have the opposite effect through desensitization of the 
carotid body, decreasing sympathetic outflow that mediates an increase in in ul  sensitivity. 
 Despite evidence that hypoxia induced insulin resistance is facilitated by increased 
sympathetic activation, there have been several investigators that have questioned this theory.  
For example, in mice exposed to 9 hours of intermittent hypoxia (FIO2=5–6% at 60 cycles/hour), 
with and without the ganglionic autonomic blocking agent hexamethonium, insulin sensitivity 
(hyperinsulinemic euglycemic clamp) was decreased 21% in response to hypoxia compared to 
normoxia.  Additionally, autonomic blockade was unable to restore insulin sensitivity during 
hypoxia111.  However, these results must be considered with caution as there are several 
limitations to the study.  It appears that the dose of hexamethonium was insuffic ent as 
autonomic blockade was unable to prevent the transient reflex bradycardia associted with 
phenylephrine infusion111.  Without complete autonomic blockade it is difficult to speculate on 
the contribution of autonomic activity to hypoxia induced insulin resistance.   
Furthermore, the effect of blocking both arms of the autonomic nervous system, 
sympathetic and parasympathetic, may have differing consequences when compared to blocking 
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each arm individually.  Sympathetic mediated increases in epinephrine have been shown to 
promote glycogenolysis while concurrently inhibiting glucose uptake, oxidation, and storage3-7.  
Likewise sympathetic mediated increases in norepinephrine is known to increase ci culating 
concentration of NEFAs 6,31, that interfere with insulin stimulated glucose uptake, leading to a 
decrease in insulin sensitivity31,32.  However, the parasympathetic system is also required for the 
maintenance of insulin sensitivity and therefore, appears to play a role in mediating insulin 
stimulated glucose uptake in hypoxia112-114.  Specifically, the parasympathetic nervous system is 
responsible for the release of hepatic insulin sensitizing substance (HISS) that accounts for 
approximately 56% of insulin stimulated glucose uptake in muscle115.  Although it is known that 
hypoxia induces an increase in sympathetic tone and a decrease in parasympathetic tone116, the 
decreased but intact parasympathetic tone during hypoxia exposure may have a signific nt effect 
on insulin sensitivity.  Thus, by blocking both arms of the autonomic nervous system it is 
impossible to conclude the extent that the sympathetic arm of the autonomic nervous system 
contributes to hypoxia induced insulin resistance.  
 In another mouse model suggesting improved glucose tolerance in response to hypoxia, 
the effect of intermittent hypoxia (FIO2=0.049; 30 seconds/min for 16 hours/day) on glucose 
tolerance was examined in the presence and absence of leptin.  In lean mice, it was shown that 
acute intermittent hypoxia decreased fasting glucose levels by 20%, improved glucose tolerance, 
and up regulated leptin mRNA expression compared normoxic conditions.  On the contrary, 
intermittent hypoxia in leptin deficient mice caused a 607% increase in circulat ng insulin levels 
that coincided with a large reduction in glucose tolerance when compared to normoxic 
conditions.  This hypoxia induced increase in circulating insulin however, was completely 
abolished with leptin infusion prior to hypoxia14.  The results of this study suggest that leptin 
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deficiency is responsible for hypoxia induced insulin resistance.  Unfortunately, the lean mice 
exposed to hypoxia demonstrated significant weight loss during the course of the study, whereas 
the obese mice maintained their weight.  Therefore, the improved insulin sensitivity in the lean 
mice was, most likely, the result of a decrease in body weight (negative energy balance) and not 
due to the up regulation of leptin as a consequence of intermittent hypoxic exposure117.  
Equivocally, the obese leptin deficient mouse is an inadequate model of human obesity as a 
majority of obese humans are hyperleptinemic as compared to the leptin defic ent model118.   
 In addition to utilizing mouse models, there has been further evidence in healthy and 
T2DM humans that suggests acute hypoxia improves glucose tolerance119,120.  In one study, 8 
healthy humans were exposed to either normoxia (362 meters) or hypoxia in an altitude chamber 
(4300 meters).  During each trial, subjects performed an Oral Glucose Tolerance Test (OGTT).  
Briefly, a 75-gram sucrose solution was ingested followed by venous blood sampling at 0, 30, 
60, 90, and 120 minutes.  Compared to normoxia, the area under the hypoxia glucose response 
curve was significantly reduced suggestive of improved glucose tolerance.  However, this was 
not due to improved insulin sensitivity as determined by HOMA-IR119.  It is important to note 
that an OGTT is not a direct measure of insulin sensitivity and a definite conclusion regarding 
insulin sensitivity cannot be drawn from it.  Likewise, the extended duration between venous 
blood sampling, especially during the first 60 minutes of the OGTT, could have masked 
differences between the two trials.   
In an additional study, examining acute hypoxia in T2DM, it was found that hypoxia 
increased insulin sensitivity (two-compartmental minimal model analysis), while the insulin 
response to a glucose load during hypoxia was 22% less than compared to normoxic 
conditions120.  Like in the previous OGTT study, insulin sensitivity was not directly measur d by 
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the hyperinsulinemic euglycemic clamp technique, but was derived from a mathe atical model 
of plasma insulin and glucose during a 4-hour intravenous glucose tolerance test (IVGTT).  
Thus, definitive conclusions cannot be made about insulin sensitivity.  Importantly, he level of 
arterial oxygen desaturation achieved in this study (SpO2=92% vs. 98%), may not have been 
enough of a stimulus to elicit a sufficient sympathetic response to attenuate i sulin sensitivity.  
Furthermore, analysis of blood glucose and insulin values took place post hypoxic exposur , 
during the 4-hour IVGTT.  The minimal hypoxic challenge that was removed upon 
commencement of the IVGTT, likely had no effect on the IVGTT.  Thus, insulin sensitivity in 
response to acute hypoxia in T2DM was not determined.    
 Overall, there seems to be conflicting findings as to whether hypoxia induces insulin 
resistance.  Several of the studies that show hypoxia decreases insulin resistance, lack direct 
measures of insulin sensitivity or are limited by other methodological concerns such as body 
mass variability, inadequate measures, and an insufficient hypoxic stimulus14,111,120.  On the 
contrary, several of the studies that suggest hypoxia induces insulin resistance, directly measure 
insulin sensitivity and limit other confounding variable such as body mass variability3,15,16.  From 
the studies that have demonstrated hypoxia induced insulin resistance it appears that increased 
sympathetic activity is a mediating effect3.  
 
Hypoxia Induced Insulin Resistance: The Sympathoadrenal System and Hypothalamic-Pituitary- 
Adrenal Axis 
 In response to stress, such as hypoxia, there is increased activity of the two major 
neurohormonal stress systems: the sympathoadrenal system or sympathetic nervous system and 
the hypothalamic-pituitary-adrenal axis121,122.  Primarily, these systems are activated under 
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conditions of stress in order to maintain systemic homeostasis.  Initially, activation of these two 
stress systems appears to be advantageous however, sustained activation of either can have 
prodigious metabolic consequences.  
The activity of the sympathoadrenal system, in response to a hypoxic stress can be 
measured either directly or indirectly123,124 .  Microneurography is a direct measuring technique 
that identifies SNS activity at the nerve by quantifying “bursts” of effer nt nerve firing that 
originate from the hypothalamus.  Commonly, the peroneal or anterior tibial nerve is the site of 
measurement for this procedure125.  Despite being an extremely accurate way to measure 
sympathetic outflow, microneurography is an invasive, tedious, and time consuming procedure.  
In contrast, indirect measures of SNS activity employ the use of plasma or urinary 
catecholamines, heart rate variability, blood pressure, or a combination of the three as indicators 
of sympathetic outflow. Unlike measuring SNS activity directly, these measur s are less 
invasive, faster, and tend correlate well with microneurography125-128.  Therefore, the term 
“elevated sympathetic nerve activity” is often used interchangeably with “elevated levels of 
catecholamines.”  These two responses are interrelated as SNS activity mediates an increase in 
catecholamines.  
Stress, such as conditions of low oxygen, has the ability to increase the activity of the 
sympathoadrenal system.   Upon acute hypoxic exposure (5260 meters) there is an immediate 
increase in muscle SNS activity that remains after four weeks of acclim tization and persists for 
a minimum of three days upon return to sea-level129.  Specifically, epinephrine has been shown 
to increase immediately upon acute altitude exposure, reaching its peak by day 2, and returning 
to sea-level values by day 6 or 73,15,17,130 .  The kinetics of the  norepinephrine response are a 
little different, with an initial rise in plasma norepinephrine occurring immediately, reaching its 
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peak within one week, and remaining elevated throughout the duration of exposure17,130,131.  
Likewise, elevated SNS activity in response to hypoxia has also been confirmed with 
microneurography132. 
The increase in sympathoadrenal activation in response to hypoxia has been attributed to 
maintaining adequate oxygen delivery to peripheral tissues despite concurrent arterial oxygen 
desaturation.  Adequate oxygen delivery during hypoxia is achieved through hemo-
concentration, unloading of plasma volume, and a subsequent increase in cardiac output for the 
maintenance of blood pressure in the face of decreasing blood volume.  Although increased SNS 
activity in response to hypoxia sounds beneficial, chronic elevation of SNS activity has been 
associated with serious metabolic consequences, such as insulin resistance5,6.    
Activation of the SNS and a successive increase in plasma catecholamines is k own to 
have substantial effects upon glucoregulation.  Specifically, catecholamines have been shown to 
increase hepatic glucose production (gluconeogenesis and glycogenolysis) and decrease glucose 
uptake, resulting in an increase in circulating plasma glucose concentrations133.  Epinephrine, 
released from the adrenal medulla, has been shown to promote glycogenolysis while 
concurrently inhibiting glucose uptake, oxidation, and storage3-7.  The epinephrine mediated 
increase in glycogenolysis is achieved through activation of glycogen phosphorylase3-5, while a 
reduction in glucose uptake occurs through epinephrine mediated inhibition of IRS-1 associated 
PI(3)K activity7.  It has been shown that IRS-1 associated PI(3)K activity is essential for insulin 
mediated translocation of GLUT 4 to the plasma membrane and subsequent glucose uptake2. 
Epinephrine inhibits glucose oxidation, via glucose-6-phosphate mediated inhibition of 
hexokinase, while concomitantly preventing glycogenesis (glucose storage) through the  
inhibition of glycogen synthase4.  The inhibition of glycogen synthase by epinephrine is 
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considered to  be the most important factor contributing to decreased Rd and subsequent increase
in plasma glucose concentrations134. 
Although the glucoregulatory effects of epinephrine have been extensively characterized, 
there is not as much information regarding norepinephrine.  From the studies that are av il ble, it 
appears that the effects of norepinephrine are only slightly different from th se of epinephrine; 
with both acting in concert to increase plasma glucose levels.  Norepinephrine and epinephrine 
are each known to increase lipolysis6,31,135  by augmenting the activity of hormone sensitive 
lipase that is responsible for the liberation of non-esterified fatty acids (NEFAs) from adipocytes.  
The ensuing increase in plasma NEFAs  inhibits insulin stimulated glucose ptake, via 
preferential fatty-acid oxidation, through a process known as the “Randle Effect136.”  Preferential 
fatty-acid oxidation leads to a decreased in insulin sensitivity via competitive oxidation31,32.  
Additionally, acute norepinephrine infusion has also been associated with hyperglycemia137,138, 
increased hepatic glycogenolysis139, and gluconeogenesis140.  Thus, it is not surprising that 
norepinephrine is reported to be a mediator of insulin resistance97,138,141,142.   A graphical 
representation of how hypoxia induces insulin resistance is shown in Figure 2. 
On the contrary, some studies suggest chronic norepinephrine exposure is insulin 
sensitizing.  Specifically, in a rat model, 10 days of continuous norepinephrine infusion (1,000 
micrograms/kg/day) causes an increase in insulin sensitivity, as measured by the 
hyperinsulinemic euglycemic clamp technique.  During 2, 6, and 200 mU/kg/h insulin infusions 
the glucose disposal rate was found to be 65, 60, and 13% greater during norepinephrine infused 
animals compared to the controls.  Despite enhancement of insulin sensitivity, norepinephrine 
infusion did not prevent an increase in hepatic glucose production98.  Down regulation of    
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beta-adrenergic receptors is most likely explanation of how chronic norepinephrine exposure can 
appear to improve insulin sensitivity.  It has previously been shown that chronic stimulation of 
beta-adrenergic receptors results in receptor down regulation143,144.  Chronic norepinephrine 
exposure, as it the case with this study, results in tissue desensitization that prevents the 
norepinephrine mediated intracellular elevations in cyclic-AMP.  Ultimately, his decreases the 
activity of hormone sensitive lipase, preventing competitive fatty-acid oxidation, while 
additionally preventing the disruption of intracellular insulin signaling.       
 In addition to the sympathoadrenal systems contributing to glucose regulation at altitude, 
the hypothalamic-pituitary-adrenal axis (cortisol) has been suggested to assist in glucoregulation.  
In response to stress, the hypothalamus releases corticotropin releasing hormone (CRH) that acts 
upon the pituitary gland causing it to secrete adrenocorticotropic hormone (ACTH).  ACTH 
targets the adrenal gland causing the release of cortisol.  Cortisol increases hepatic glucose 
production via gluconeogenesis and glycogenolysis, decreasing glucose uptake through e 
inhibition of glycogen synthase activity96,145.   
In response to acute hypoxia, several studies have shown that levels of plasma cortisol 
remain unchanged when compared to sea-level3,146-148.   Alternatively, several opposing studies 
show an increase in cortisol concentrations as a result of hypoxia149.  For example, in individuals 
exposed to 2 days of high altitude exposure, plasma cortisol concentrations were elevated insulin 
sensitivity was decreased16.  Although cortisol promotes insulin resistance by increasing hepatic 
gluconeogenesis and attenuating the activity of glycogen synthase96,150,151, its role in  hypoxic 
glucose regulation remains debatable. 
 In summary, the sympathoadrenal system is elevated under conditions of low oxygen.  
Epinephrine and norepinephrine play critical roles in the elevation of plasma glucose evels 
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under such conditions.  The hypothalamic-pituitary-adrenal axis may also play a role in elevating 
plasma glucose levels in response to hypoxia through the actions of cortisol.  However, the 
contributions of cortisol in elevating plasma glucose during hypoxia remain uncertai . 
 
Hypoxia Induced Insulin Resistance: Contributions of Additional Hematologic Factors 
It appears unlikely, that elevated SNS activity is exclusively responsible for hypoxia 
induced insulin resistance. In addition to catecholamines and non-esterified fatty acids, 
mediating hypoxia induced insulin resistance, there are several other circulating factors regulated 
by hypoxia that may influence insulin sensitivity.  These factors include: adiponectin, pigment 
epithelium derived factor, oxidized low density lipoproteins, tumor necrosis factor-lpha.   
Adiponectin is an adipokine, a protein secreted primarily from white adipose tissue, hat 
is associated with insulin-sensitizing, anti-inflammatory, and anti-angiogenic effects 152.  
Adiponectin has been shown to be decreased in insulin resistance and T2DM153.  The insulin 
sensitizing effects of adiponectin occur through receptor binding (AdipoR1) and activation of 
AMP-activated protein kinase and proliferator-activated receptor gamma coactivator-1 alpha 
(PGC-1α)154.  Subsequently, this activation favors glucose uptake into cells and increased 
oxidative capacity.  Interestingly, adiponectin expression and secretion is inhibited by 
hypoxia155-157.  
Similar to adiponectin, pigment-epithelium derived factor (PEDF) is also an adipokine 
that is a known regulator of insulin sensitivity, oxidative stress, inflammation and 
angiogenesis158.  PEDF, unlike adiponectin, is inversely associated with insulin sensitivity159 and 
elevated in insulin resistance160.  It has been suggested that PEDF prompts insulin resistance 
through activation of pro-inflammatory pathways, stimulation of lipolysis, and promoti n f 
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ectopic lipid accumulation that  interfere with insulin signaling161.  Hypoxia has been shown to 
up regulate mRNA and  protein levels of PEDF162.    
In addition to regulating adiponectin and pigment epithelium derived factor, hypoxia also 
increases systemic oxidative stress163-165.  High levels of oxidative stress have been shown to 
activate the JNK signaling pathway, which inhibits activation of IRS-1 and trslocation of 
GLUT 4 to the plasma membrane166.  Therefore, it is not surprising that insulin resistance is 
characterized by elevated levels of oxidative stress167.   
A final factor to be considered as a potential mediator of hypoxia induced insulin 
resistance is tumor necrosis factor alpha (TNF-α).  TNF-α is a cytokine that is most often 
associated with inflammation.  It has been implicated in insulin resistance as it is highly 
expressed in obese individuals44,  obese mice lacking tumor necrosis factor alpha receptors are 
protected from insulin resistance168, and infusion of tumor necrosis alpha in rats causes insulin 
resistance169.  Mechanistically, TNF-α has been suggested to induce insulin resistance through its 
inhibitory effects on both the insulin receptor and IRS proteins.  Specifically, TNF-α has been 
shown to inhibit the activating tyrosine phosphorylation on the insulin receptor and IRS proteins 
that are crucial for the transduction of the insulin signal44,170.  Hypoxia has been shown to 
positively regulate the production of TNF-α171-173. 
 
Clinical Conditions of Hypoxia: OSA and COPD 
OSA affects approximately 3-7% of adult men and 2-5% of adult women and is 
characterized by momentary cessations of breathing (apneas) or decreases in breath amplitude 
(hypopneas) that are sufficient to induce hypoxemia and hypercapnia during sleep19.  These 
hypopneas and apneas are predominantly caused by: a compromised upper airway, a decrease in 
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brain stem respiratory motor output, and the synchronization of these two events over time20.  
These events lead to repeated bouts of nocturnal intermittent hypoxia as defined  by d creased 
arterial oxygen saturation174. 
The risk factors for developing OSA include: obesity, T2DM, hypertension, gender, 
specifics of cranial facial structures, and age175.    However, obesity, especially visceral 
adiposity,  has the greatest influence in promoting the development of OSA176.  Obesity has 
several mechanisms by which it can contribute to the development of OSA.  It can cause 
narrowing of the upper airway by physically decreasing lung volume and reducing the expansive 
“tug” that the trachea experiences from incoming air.  Furthermore, adipose tissu releases 
various humoral factors such as leptin, TNF-α, and IL-620.  Leptin, in addition to influencing 
satiety and metabolism, can also act as a respiratory stimulant20,177.  Impairment of leptin 
signaling pathways, as can be the case in obese humans, causes respiratory depression in mice 
and hypoventilation syndrome in humans that can result in OSA177-179.  In addition to 
contributing directly to OSA,  the inflammatory cytokines released from excessive adipose 
tissue, such as TNF-α and IL-6,  can also foster the development of insulin resistance180,181.  
However, despite obesity being a primary risk factor for the development of OSA,  there are 
many non-obese individuals that also suffer from OSA182.  Therefore, suggesting OSA is not 
merely a consequence of obesity. 
  Similar to OSA, COPD is also a disease of hypoxia characterized by air-flow 
obstruction and arterial oxygen desaturation.  Conditions previously known as chronic bronchitis 
and emphysema are now classified as COPD, all of which stem from chronic inflammation in the 
airways primarily due to regular exposure to tobacco smoke, noxious gases, or fine part culates.  
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Unlike OSA which is characterized by reversible intermittent hypoxia, COPD is a chronic 
disease that is progressive and irreversible183.    
The majority of individuals afflicted with either OSA or COPD display increased SNS 
activity22,23,184,185.  Specifically, the hypoxic stimuli associated with OSA induces an enhanced 
chemoreceptor response that increases sympathetic outflow186.   The increased sympathetic 
outflow is modulated by both the central and peripheral chemoreceptors.  The central 
chemoreceptors, found within the brainstem respond to hypercapnia whereas the perip ral 
chemoreceptors (carotid chemoreceptors), located within the carotid bodies, respond to hypoxia.  
When activated, these chemoreceptors promote  hyperventilation and increased sympathetic 
outflow186.  With repeated bouts intermittent hypoxia as seen in OSA, the enhancement of the 
peripheral hypoxic chemoreflex response is magnified, resulting in an even greater increase in 
sympathetic nerve activity that would be exposed during hypoxia exposure186,187.  Therefore, the 
severity of hypoxia, in OSA and COPD, is positively associated with the degree of increased 
SNS activity188.       
Elevated SNS activity in OSA patients is demonstrate by a biphasic catechol mine 
response.  During nocturnal periods, when intermittent hypoxia is most prevalent, epinephrine 
levels are elevated189.  On the other hand, during the day, when intermittent hypoxia is not 
present, norepinephrine levels are elevated while epinephrine remained unchanged compared to 
non-OSA controls190.  This is comparable to what is found when healthy individuals are exposed 
to hypoxia, albeit over a much shorter time period. 
One common treatment for OSA involves the use of continuous positive airway pressure 
(CPAP) while sleeping.  CPAP is a breathing therapy that utilizes continuous pressurized air, 
from a face mask or nasal pillow that forces an individual to initiate each breath, thereby 
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eliminating hypopneas and apneas.  CPAP is an effective treatment for OSA191 and also 
decreases the elevated sympathetic activity typically seen in OSA192-195.  Additionally, oxygen 
supplementation that eliminates hypoxic exposure in COPD patients has also been shown to 
favorably alter autonomic activity30.  Thus, hypoxic exposure as a result of OSA and COPD is 
characterized by increased SNS activity that is attenuated upon cessation of hypoxic 
exposure185,196-198.      
OSA and COPD have also been associated with a  high prevalence of insulin resistac  
and impaired glucose tolerance 24,25,199,200, independent of other factors such as age, sex, and 
body mass24.  It has been demonstrated in several studies that T2DM patients, or those with 
impaired glucose metabolism, have an extremely high prevalence of OSA25,201,202.  Interestingly, 
CPAP reduces elevated sympathetic activity in OSA patients and improves insulin sensitivity.  
Improvements in insulin sensitivity have been shown with only two days of CPAP treatment and 
these improvements remained until cessation of therapy29,175.  Therefore, it is reasonable to 
suggest that the hypoxic exposure as the result of OSA or COPD increases SNS activity and this 
increased SNS activity is partially mediating the high prevalence of insulin resistance found in 
these populations.  Likewise, the improvements in insulin sensitivity associated with CPAP 
appear to be facilitated by a decrease in SNS activity.  There appears to be a logical link between 
hypoxia, elevated SNS activity, and insulin resistance. 
Alternatively, it is possible that the hypothalamic-pituitary-adrenal axis response to 
hypoxic stress could be mediating the high prevalence of insulin resistance in OSA and COPD 
patients.  Specifically, under periods of stress the hypothalamic-pituitary-adrenal axis promotes 
the secretion of cortisol.  Cortisol is known to have potent glucoregulatory effects by increasing 
hepatic glucose production and decreasing glucose uptake96,145.  However, there is conflicting 
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data regarding serum cortisol concentrations in OSA and COPD patients.  Several studies have 
demonstrated non-significant differences in serum cortisol concentrations of OSA and COPD 
patients compared to healthy controls203,204, while others have found  serum cortisol 
concentrations to be elevated in OSA and COPD patients205,206.   Therefore, the extent to which 
cortisol could be mediating the effect of insulin resistance in OSA and COPD populati n remains 
to be seen. 
 In summary, OSA and COPD are characterized by hypoxia, increased SNS activity, and 
a high prevalence of insulin resistance.  Hypoxia is known to enhance the peripheral 
chemoreceptor response that is responsible for increasing sympathetic outflow in OSA and 
COPD.  CPAP, a common treatment option for OSA, eliminates nocturnal bouts of intermittent 
hypoxia, prevents arterial oxygen desaturation, decreases SNS activity, and improves insulin 
sensitivity.  This suggests that elevated SNS activity is mediating the high prevalence of hypoxia 
induced insulin resistance found in these populations. 
 
Summary 
Insulin, one of the primary glucoregulatory hormones, promotes glucose homostasis 
through a series of successive steps that lead to the translocation of glucose transporter proteins 
to the plasma membrane and subsequent glucose uptake9.  Unfavorable perturbations to either 
the insulin signaling cascade or GLUT 4 translocation can result in dysregulation of glucose 
homeostasis and insulin resistance2.  Specifically, acute and chronic exposure to hypoxia is 
known to reduce insulin sensitivity while simultaneously increasing the activity of the 
sympathetic nervous system3,15,16.  Additionally, obstructive sleep apnea (OSA) and chronic 
obstructive pulmonary disease (COPD) are clinical conditions characterized by hypoxia, elevated 
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SNS activity, and a high prevalence of insulin resistance201.  In contrast to hypoxic exposure and 
hypoxic related diseases, hyperoxia has been shown to improve insulin sensitivity while 
concomitantly decreasing SNS activity18.  Consistent with this, continuous positive airway 
pressure (CPAP), a common OSA treatment, has proven effective in abol shing nocturnal bouts 
of intermittent hypoxia, enhancing insulin sensitivity and diminishing SNS activity29.  Although 
the underlying mechanism of hypoxia induced insulin resistance remains unclear, it appears that 
elevated SNS activity may be a mediating factor3.  It is unlikely, that elevated sympathetic 
nervous system activity is exclusively responsible for hypoxia induced insulin resistance.  
Therefore, it is important to consider other known circulating insul sensitizing and 
desensitizing factors that are regulated by hypoxia. Identification of the mechanism(s) underlying 
hypoxia induced insulin resistance may provide effective treatment options for hypoxia-related 
disease.  Effective treatments have the potential to reduce the prevalence or development of 


















 We studied a total of 12 healthy, adult males. Recruitment criteria included: being 
between the ages of 18 and 65 years, non-smokers or had not smoked in the previous 2-years, 
normotensive (<140/90 mmHg), normoglycemic (fasting blood glucose concentratio  <100 
mg/dl (<5.5 mmol/l )), resting heart rate of greater than 40 beats per minute, were not taking 
medications or supplements that may have confounded the interpretation of data, and were 
willing to abstain from exercise for 48 hours prior to testing.  The participants were classified as 
healthy, based upon a medical history questionnaire, and were free of any cardiac abnormalities 
as determined by a 12-lead beat-by-beat electrocardiogram and blood pressure measurements 
both at rest and during an incremental exercise test.  The nature, purpose, and risks of the study 
were explained to each subject before written informed consent was obtained.  The experim ntal 
protocol conformed to the standards set forth in the Declaration of Helsinki and was approved by 
the Institutional Review Board at Colorado State University.  
 
Overall Experimental Design 
 All measurements were made at the Colorado State University Human Performance and 
Clinical Research Laboratory.  The hypothesis was addressed using a randomized repeated 
measures design.  Independent variables included normoxia/hypoxia and intact SNS/inhibited 
SNS via 48-hour transdermal clonidine administration.  The primary dependent variable, insulin 
sensitivity, was determined by the hyperinsulinemic euglycemic clamp technique93,159.   
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Following screening procedures (health history questionnaire, graded exercis  t st, 12-
lead electrocardiogram, and measures of body composition) insulin sensitivity was determined, 
in random order, during four conditions:  normoxia (FIO2=0.21), hypoxia (FIO2=0.11), normoxia 
and SNS inhibition (48-hour transdermal clonidine administration (Catapres-TTS; 0.2mg/day)), 
and hypoxia and SNS inhibition.  Each trial was separated by a minimum of 7 days an  subjects 





Fat mass and fat-free mass were measured using dual-energy X-ray absorptiometry 
(Hologic, Discovery W, QDR Series, Bedford, MA, USA).  Body height was measured to the 
nearest 1 millimeter and body weight to the nearest 100 grams using a stadiome er and beam 
scale (Detecto, Webb City, MO, USA).  Body mass index was calculated as body mass/height2 
(kg/m2). Maximal oxygen uptake (VO2max) was determined with a metabolic cart (Parvo Medics, 
Sandy, UT, USA) during a progressive, maximal cycle ergometer (Velotron Dynafit Pro, 
RacerMate, Inc., Seattle, WA, USA) test.  Briefly, subjects cycled on a cycle ergometer at an 
increasing work rate until exhaustion.  A valid VO2max was determined by whether three of the 
following four criteria were satisfied: heart rate within 10 beats/min of their age-related 
maximum207, plateau in VO2max despite increasing work rate, RER>1.10, and a rating of 
perceived exertion ≥ 18208. 
 
Normoxic/Hypoxic Gas Breathing 
For all trials, subjects reported to the laboratory between the hours of 0600 and 0800 
following a 12 hour fast, 48 hour abstention from exercise, and after having consumed a 
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standardized meal (Ensure and Power Bar) in addition to their normal diet the evening before 
(verbal confirmation).  Upon arrival, subjects were weighed (Detecto, Webb City, MO, USA), 
instrumented for determination of beat-by-beat heart rate (3-lead electrocardiogram), blood 
pressure (automated physiological monitor: Cardiocap 5, GE Datex-Ohmeda, Maison, WI 
USA), and oxygen saturation (Pulse oximetry: Cardiocap 5, GE Datex-Ohmeda, Maison, WI 
USA).   
Normoxia and hypoxia were simulated with administration of a 21% (normoxic) or 11% 
(hypoxic) oxygen dry gas mixture (Airgas Intermountain, Inc., Denver, CO, USA) on the day of 
the euglycemic hyperinsulinemic clamp procedure; commencing 15 minutes prior to, and 
continuing throughout the duration of the procedure. All measurements were performed betw en 
0600 and 1300 in a dimly lit room at a comfortable temperature (approximately 23°C) with 
subjects quietly resting in a semi-recumbent position.  An intravenous catheter was placed in an 
antecubital and contralateral dorsal hand vein, and baseline venous blood samples were obtained 
from the contralateral dorsal hand vein.   
Thereafter, subjects began breathing either a normoxic or  hypoxic gas mixture.  Subjects 
inspired via an airtight facemask (7450 Series; Hans Rudolph, Inc., Shawnee, Kansas, USA) 
attached to a three-way, non-rebreathing valve (2730 Series: Hans Rudolph, Inc., Shawnee, 
Kansas, MO, USA), connected via hose to a 100 liter, non-diffusing gas bag (6000 Series: Hans 
Rudolph, Inc., Shawnee, Kansas, MO, USA) filled with either the normoxic or hypoxic gas. 
After 15-minutes of baseline gas breathing, the measurement of insulin sensitivity 
commenced.  Subjects continued to breathe either the normoxic or hypoxic gas mixturefor the 
remainder of the 180-minute protocol.  Heart rate, blood pressure, and oxyhemoglobin saturation 
were monitored continuously and recorded every 15 minutes.   
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Insulin Sensitivity via Hyperinsulinemic Euglycemic Clamp Technique 
 
The clamp is considered, by many, to be the gold-standard measurement of insulin 
sensitivity and has been previously utilized in the lab93,159,209.  Briefly, antecubital catheters were 
utilized for infusion of insulin and glucose, while contralateral dorsal hand vein catheters, 
warmed via a heated blanket (Kaz, Inc., Hudson, NY, USA) were utilized for arterializ d-venous 
blood sampling. A descending dose (127–40 mU/(m body surface area)2/min) of regular insulin 
(Humulin, Eli Lilly and Co., Indianapolis, IN, USA) was administered over the first 10 min, 
followed by a continuous infusion (40 mU/(m body surface area)2/min) from 10 to 180 min. 
Administration of a 20% dextrose solution was initiated at 4 minutes (2 mg/(kg body mass)/ in) 
and adjusted as necessary to maintain blood glucose at a concentration of 90 mg/dl (5 mo /l) 
throughout the clamp. Arterialized venous blood samples (~1 ml) were obtained every 5 minutes 
and blood glucose concentration was analyzed immediately using an automated device (2300 
STAT Plus Glucose Lactate Analyzer, YSI Inc., Yellow Springs, OH, USA).  Insulin sensitivity 
was determined from the mean rate of glucose infusion during the last 30 minutes of th  clamp 
and expressed as milligrams of glucose per kilogram body weight per minute.  
 
Inhibition of the Sympathetic Nervous System 
  Inhibition of the SNS began 48-hours prior to two of the four laboratory visits.  The SNS 
was inhibited through the administration of transdermal clonidine to the upper arm (Catapres-
TTS; 0.2 mg/day). Clonidine is a common hypertension medication that is typicall administered 
in doses ranging from 0.1mg/day to 0.3mg/day210,211.  Its mechanism of action is via pre-
junctional stimulation of alpha-2-adrenegic receptors, including those located in the locus 
coeruleus of the brain stem, resulting in centrally mediated peripheral sympathoadrenal 
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inhibition, as reflected by decreased norepinephrine release212 and attenuated muscle SNS 
activity213,214.  Subjects were supplied with emergency contact information and were required to 
report for a follow-up blood pressure measurement 24 hours after clonidine administration, o be 
monitored for adverse effects, such as hypotension and skin irritation.  
 
Blood Collection and Analysis 
 
Venous blood samples were also collected at time points: -15 minutes (baseline prior to 
administration of supplemental gas), 0 minutes, 30 minutes, 60 minutes, 120 minutes, and 180 
minutes.  All times corresponding to the start of the clamp.  Of the -15 minute, 0 minute, and 180 
minute venous blood samples:  approximately 10 ml was preserved with K3 
ethylenediaminetetraacetic acid (Vacuette EDTA tubes - Non-ridged (pull cap), Greiner Bio-One 
North America, Inc., Monroe, NC, USA),  approximately 10 ml was transferred into atube 
containing a silica clot activator, polymer gel, silicone-coated interior (Vacutainer SST Tube 
with Silica Clot Activator, Polymer Gel, Silicone-Coated Interior, BD, Franklin Lakes, NJ, 
USA),  and approximately 5 ml was preserved with ethylene glycol tetraac tic acid/glutathione).  
Of the 30 minute, 60 minute, and 120 minute venous blood samples: approximately 5 ml was 
preserved with ethylene glycol tetraacetic acid/glutathione.   Samples preserved with K3 
ethylenediaminetetraacetic acid and glycol tetraacetic acid/glutathione were collected in chilled 
tubes, placed immediately on ice and centrifuged (-4°C and 3600 rpm) within 60 minutes of 
collection to isolate plasma. Samples collected in silica clot activator, polymer gel, silicone-
coated interior plasma tubes, were collected and remained at room temperature fo  
approximately 30 minutes after sample collection.  Samples were then centrifuged (-4°C and 
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3600 rpm) within 60 minutes of collection to isolate serum.  Subsequently, all samples were 
stored at –80°C until analysis.   
Enzyme-linked immunosorbent assays (ELISA) were used to measure, in duplicate, 
plasma concentrations of C-peptide, adiponectin, and pigment epithelium derived factor (all 
Millipore Corporation, Billerica, Massachusetts, USA), insulin (ALPCO Diagnostics, Salem, 
New Hampshire, USA), oxidized low density lipoproteins (ALPCO Diagnostics, Salem, New 
Hampshire, USA), tumor necrosis factor-alpha (R&D Systems, Inc., Minneapolis, Minnesota, 
USA), catecholamines (Rocky Mountain Diagnostics, Colorado Springs, Colorado, USA), and 
non-esterified fatty acids (Wako Diagnostics, Richmond, Virginia, USA). 
 
Statistical Analysis 
 This study was designed as a randomized, repeated measures study.  Therefore, we 
examined potential differences in insulin sensitivity due to hypoxia/normoxia and intact/inhibited 
SNS using repeated measures analysis of variance (ANOVA).  If differenc s were detected, a 
Newman-Keuls post hoc analysis was performed to determine the location of these diff rences. 
Plasma catecholamines, compared to control (normoxic gas breathing, intact SNS) were 
analyzed by calculating the area under the curve, via the trapezoidal method, above baseline.  
Subsequently, these values were compared using repeated measures ANOVA.  Other circulating 
factors including C-peptide, adiponectin, pigment epithelium derived factor, oxidized low 
density lipoproteins, tumor necrosis factor-alpha, and non-esterified fatty acids were also 
analyzed with repeated measures ANOVA including time (-15, 0, 180 minutes) as an addition l 








 There were 12 subjects recruited for the study and a total of 10 subjects completed the 
entire protocol.  Two of the initial 12 subjects were excluded from the study due to symptoms 
associated with hypoxia intolerance including: nausea and headache.  These individuals 
recovered quickly, upon cessation of hypoxic gas breathing, but were excluded from the study.  
The remaining group of 10 subjects was: young, normal weight, normal body mass index, 
normotensive, normal fasting blood glucose, and were of average aerobic fitness.  Details of 
these subject characteristics are shown in Table 1.  
 
Oxyhemoglobin Saturation 
 Hypoxic gas breathing caused a decrease (P<0.01) in oxyhemoglobin saturation, 
compared to normoxia (Figure 3), whereas clonidine had no effect (P>0.25). 
 
Plasma Catecholamines 
 Plasma catecholamine concentrations were determined prior to and throughout the clamp 
procedure under each of the four conditions: normoxic gas breathing (FIO2=0.21), hypoxic gas 
breathing (FIO2=0.11), normoxic gas breathing and clonidine administration (FIO2=0.21; 
Catapres-TTS 0.2mg/day-48 hours), and hypoxic gas breathing and clonidine administratio  
(FIO2=0.11; Catapres-TTS 0.2mg/day-48 hours).  During basal or baseline conditions, prior to
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normoxic/hypoxic gas breathing, clonidine decreased norepinephrine (P=0.05) while there was 
no significant change in epinephrine (P=0.16).   
 Overall, the area under the norepinephrine curve was increased with hypoxia (137±13%; 
P=0.02) compared to normoxia, while clonidine prevented the hypoxia induced increase 
norepinephrine (94±14%; P=0.43).  The area under the epinephrine curve was increased in 
hypoxia (371±40%; P<0.001) compared to normoxia.  However, clonidine was ineffective at 
preventing the hypoxia induced increase in epinephrine (346±82%; P<0.001).  Plasma 
catecholamine data is shown in Figures 4 and 5.     
 
Heart Rate and Blood Pressure 
 At baseline, prior to either normoxic or hypoxic gas breathing, clonidine decreased 
resting heart rate (P<0.04) and resting systolic blood pressure (P<0.05) while diastolic blood 
pressure remained unchanged (P<0.08).   
 During the clamp with hypoxic gas breathing, heart rate was higher (P<0.001) compared 
to the normoxic clamp.  Clonidine decreased the hypoxic clamp induced elevation in heart rate 
(P=0.006).   
 The hypoxic clamp did not have an effect on diastolic blood pressure compared to the 
normoxic clamp (P=0.10).  Clonidine administration, compared to non-clonidine administration, 
decreased diastolic blood pressure during the hypoxic and normoxic clamps (P<0.001).   Systolic 
blood pressure remained unchanged under hypoxic and normoxic clamps, with or without 
administration of clonidine (P>0.41).  Heart rate and blood pressure data, under all conditions, 




The Hyperinsulinemic Euglycemic Clamp and Insulin Sensitivity  
Insulin sensitivity was determined by the clamp procedure with greater glucose infusion 
rates indicative in greater insulin sensitivity. The glucose infusion rates ( djusted for fat free 
mass and circulating insulin concentration) required to maintain blood glucose concentration at 5 
mmol/l during administration of insulin under: normoxic gas breathing (FIO2=0.21), hypoxic gas 
breathing (FIO2=0.11), normoxic gas breathing and clonidine administration (FIO2=0.21; 
Catapres-TTS 0.2mg/day for 48 hours), and hypoxic gas breathing and clonidine administratio  
(FIO2=0.11; Catapres-TTS 0.2mg/day for 48 hours) are shown in Figure 6.    
 Compared to normoxia, insulin sensitivity was decreased during hypoxia (P=0.03).  In 
contrast, insulin sensitivity remained unchanged during normoxia and sympathetic in ib tion 
(P=0.86), and hypoxia and sympathetic inhibition (P=0.23).  
At the end of the clamp (180 minutes) there was no difference in blood glucose 
concentrations between all conditions (Normoxia: 90.1 mg/dl±0.7 (5.00±0.04 mmol/l); 
Normoxia-Clonidine: 90.5±0.5 (5.02±0.03); Hypoxia: 89.9±1.1 (4.99±0.06); Hypoxia-Clonidine: 
90.8±0.7 (5.04±0.04); P=0.77) suggestive of successful glucose clamping. 
Plasma insulin concentrations at the end of the clamp were approximately 10-fold higher 
than when compared to basal, pre-clamp concentrations (P<0.001), with there being no 
interaction between time, hypoxia and sympathetic inhibition (Figure 7; P=0.22).   The increase 
in end-clamp plasma insulin concentrations is attributed to exogenous insulin administration as 
there was no difference in pre-clamp and end-clamp concentrations of C-peptide (Figur 8; 
P>0.41).  It is known that C-peptide is a good indicator or pancreatic insulin release, with 
increasing endogenous insulin production being mirrored by an equimolar increase in C-
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peptide215.  Similar to plasma insulin concentrations, there was no interaction between tim, 
hypoxia and sympathetic inhibition with C-peptide (Figure 8; P>0.84). 
 
Additional Hematologic Factors 
 We also examined additional circulating hematological factors that are traditionally 
known to be modulated by hypoxia and/or have an effect on insulin sensitivity including: non-
esterified fatty acids (Figure 9), pigment epithelium derived factor (Figure 10), oxidized low 
density lipoproteins (Figure 11), tumor necrosis factor-alpha (Figure 12), and adiponectin 
(Figure 13). However, it was found that none of these factors were influenced by time, hypoxia 



















This study was designed to elucidate whether elevated SNS activity is a mediator of 
hypoxia induced insulin resistance.  During the hypoxic clamp, the glucose infusion rate was 
attenuated by approximately 50%, compared to the normoxia and normoxia/clonidine 
interventions.  However, during the hypoxia/clonidine trial, the differences in glucose infusion 
rates were abolished compared to the normoxia and normoxia/clonidine interventions.  Based 
upon these findings, effective SNS inhibition and improved insulin sensitivity with SNS 
inhibition, we are confident in our conclusion that inhibition of the sympathetic nervous system 
attenuates hypoxia induced insulin resistance.  
The observation of hypoxia induced insulin resistance in our study is consistent with 
previous studies that have demonstrated insulin resistance in healthy adult humans and animals 
exposed to acute, chronic, and intermittent hypoxia3,14-16.  Although there have been several 
studies that have suggested elevated SNS activity as a mediator of hypoxia induced i s lin 
resistance3, few have directly addressed this issue.  Of those that have examined elevated SNS 
activity as a mediator of hypoxia induced insulin resistance, the results are inconclusive.  For 
example, in one study, despite a concurrent rise in epinephrine concentrations and a decrease in 
glucose tolerance, it was concluded that epinephrine was not mediating the decrease in insulin 
sensitivity as alpha-1-adrenergic antagonism was unable to ameliorate the effect15.    However, 
alpha-1-adrenergic antagonism is unlikely to influence sympathetic stimulaion of 
glycogenolysis, hepatic glucose production, or inhibition of insulin release as these are primarily 
beta-adrenergic and alpha-2-adrenergic receptor mediated functions104,105.  Similarly,  in mice 
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exposed to 9 hours of intermittent hypoxia, with and without the  ganglionic autonomic blocking 
agent hexamethonium, insulin sensitivity was decreased in response to hypoxia (comp red to 
control, normoxic conditions) and was not restored with autonomic blockade111.    However, the 
dose of hexamethonium administered was ineffective, indicative of its inability to prevent the 
transient reflex bradycardia associated with phenylephrine infusion111.  Without complete 
autonomic blockade it is difficult to speculate on the contribution of autonomic activity to 
hypoxia induced insulin resistance.  In addition, the effect of blocking both arms of the 
autonomic nervous system, sympathetic and parasympathetic, may have differing consequences, 
compared to blocking each arm individually.  The parasympathetic system is required for 
maintaining insulin sensitivity and therefore plays a critical role in mediating insulin stimulated 
glucose uptake in hypoxia112.  Although there have been several studies that have attempted to 
address the role of the sympathetic nervous system in hypoxia induced insulin resistac , most of 
these studies have shortcomings.      
Taking into consideration the ineffectiveness of peripheral alpha-1-adrenergic 
antagonism and ganglionic autonomic blockade, we chose to direct our aim towards central 
inhibition of the sympathetic nervous system, with the anti-hypertensive drug clonidine.  
Clonidine, as previously mentioned, acts centrally upon pre-synaptic alpha-2-adrenergic 
receptors in the brainstem allowing potassium influx of the pre-synaptic neuron, 
hyperpolarization, and inhibition pre-synaptic neurotransmitter release216.  Administration of 
clonidine, at comparable dosing to that used in our study, has been shown to directly decrease 
skeletal muscle sympathetic nerve activity143,214,  inhibit norepinephrine release, and decrease 
plasma norepinephrine concentrations143,212.  In agreement with these previous studies, we 
48 
 
observed similar decreases in basal plasma norepinephrine concentrations, heart rate and systolic 
blood pressure, and attenuation of the norepinephrine and heart rate responses to hypoxia. 
Upon close examination of glucose infusion rates across conditions, we demonstrated that 
hypoxia causes a 50% decrease in glucose infusion compared to normoxia.  However, when 
comparing the glucose infusion rates during hypoxia/clonidine to that of normoxia, although 
there is no significant difference between the two conditions, it appears that glucose infusion 
rates during hypoxia/clonidine is approximately 75% of that during normoxia.  However, 
extreme caution must be taken when making this comparison as there was no significant 
difference in glucose infusion rates between conditions.  
The incomplete abrogation of hypoxia induced insulin resistance in the presence of 
clonidine can be explained by variations in plasma catecholamine levels. Despite clon dine 
effectively preventing the hypoxia induced rise in norepinephrine, it did not inhibit te hypoxia 
induced rise in epinephrine.  This is in accordance with previous findings143.  Epinephrine is 
potent mediator of glucose homeostasis as it can induce insulin resistance by promoting 
glycogenolysis while inhibiting glucose uptake, oxidation, and storage3-7.  Specifically 
epinephrine’s effects are mediated through the activation of glycogen phosphorylase3-5, and  
inhibition of IRS-1 associated PI(3)K activity7, hexokinase, and glycogen synthase activities4.  
Therefore, the failure of clonidine to inhibit the hypoxia induced rise in epinephrine may explain 
why we did not see a complete abrogation of glucose infusion rates when comparing conditions 
of normoxia to that of hypoxia/clonidine.  The inhibition of hypoxia induced increases in both 
plasma epinephrine and norepinephrine could be addressed in future studies with the 
administration of a tyrosine hydroxylase inhibitor such as alpha-methyl-p-tyrosine.   
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The positive effect on glucose infusion rates under conditions of hypoxia/clonidine 
appears to be the result of clonidine induced inhibition of hypoxia stimulated norepinephrine 
release.  Norepinephrine is known to invoke lipolysis6,31  by increasing the activity of hormone 
sensitivity lipase which is responsible for the release of non-esterified fatty acids from 
adipocytes into systemic circulation.  The subsequent increase in plasma non-esterified fatty 
acids interferes with insulin stimulated glucose uptake, leading to a decreas  in insulin 
sensitivity31,32.  However, in the current investigation we did not demonstrate a significant 
(P=0.058) interaction between time, hypoxia, and sympathetic inhibition for non-esterifi d fatty 
acids.  Despite not reaching a level significance, clonidine’s insulin sensitizing actions, 
potentially, resulted from inhibition of norepinephrine release, subsequent inhibition of lipolysis, 
and attenuation of plasma non-esterified fatty acid levels.  
In addition to catecholamines and non-esterified fatty acids mediating hypoxia induced 
insulin resistance, we also considered several other factors that are known to be regulated by 
hypoxia and may have the potential to influence insulin sensitivity.  These factors include: 
adiponectin, pigment epithelium derived factor, oxidized low density lipoproteins (marker of 
oxidative stress), tumor necrosis factor-alpha (marker of inflammation).  Despite ach of these 
circulating factors being regulated by hypoxia and directly or indirectly associated with insulin 
resistance, none were affected by hypoxia or sympathetic inhibition.  There is the possibility that, 
although none of these factors reached significance, additive small changes in each factor could 
be enough to induce insulin resistance. 
 Aside from circulating cytokines, oxidative stress, and inflammation having the po ential 
to cause variations in glucose uptake, hepatic and muscle glycogen content can also have an 
effect.  Blood glucose it typically maintained within narrow limits.  During periods when blood 
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glucose is elevated the activity of glycogen synthase is increased, stimulating the removal of 
glucose from the blood and promoting storage as glycogen in liver and muscle tissue.  In 
addition, acute bouts of exercise are known to deplete muscle glycogen stores, increase the 
activity of glycogen synthase, and ultimately result in increased post-exercise insulin 
sensitivity217.   With this in mind, we attempted to ensure equal muscle and liver glycogen 
content across all trials for each subject.  This was accomplished by having subject  refrain from 
exercise for 48-hours prior to each intervention, having them fast for 12-hours prior to the 
commencement of each study, and providing a standardized meal the evening before each 
intervention.  Although we attempted to limit variability in glycogen content between trials, we 
did not obtain muscle or liver tissue for direct measurements.  This could be addressed in future 
studies. 
 There are several additional limitations that warrant discussion.  As mentioned, the 
hyperinsulinemic euglycemic clamp technique is considered the gold standard for the 
measurement of insulin sensitivity209.  However, the one-step clamp, utilized for the purposes of 
our study, does not provide information about hepatic insulin sensitivity or renal insulin 
sensitivity.  It is known that epinephrine stimulates hepatic218 and renal gluconeogenesis219.  
Therefore, it is possible that the observed hypoxia induced insulin resistance is the result of 
epinephrine mediated gluconeogenesis.  However, this appears unlikely, given the approximate 
ten-fold increase in circulating insulin levels during the euglycemic hyperinsulinemic clamp 
procedure.  For future direction this could be addressed through the incorporation of a two-step 
clamp and labeled glucose infusion.   
 In addition to the lack of data on hepatic insulin sensitivity, we also lack data on a 
peripheral mechanism of hypoxia induced insulin resistance.  Specifically, we did not examine 
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muscle or adipose tissue for possible alterations in the multifaceted steps of he insulin signaling 
pathway and GLUT 4 translocation.  Muscle and adipose tissue biopsies with subsequent 
analysis would be effective in addressing this issue.   
 Despite examining several circulating factors associated with insulin sensitivity and 
hypoxia we did not address cortisol levels.  Previous research has implicated cortisol in induction 
of insulin resistance95 through its role in decreasing the activity of glycogen synthase in skeletal 
muscle96.  Cortisol concentrations have been shown to be elevated during exposure to hypoxia16.  
Therefore, it is possible that elevated cortisol levels in response to hypoxia could be in part 
responsible for hypoxia induced insulin resistance.    
 In order to avoid the monthly hormonal fluctuations of females, our subject recruitment 
was limited to males.  Therefore, our results can only be directly applied to males.  However, 
based upon previous observations of hypoxia induced insulin resistance in women, we do not 
expect there to be any sex differences15.   
 Sympathetic inhibition was achieved through transdermal clonidine administrat on. 
Instead of a relative dose, we used an absolute dose of clonidine (0.2mg/day) for eachindividual.  
Ideally, we would have standardized our clonidine administration, relative to body surface a ea, 
body mass, or fat-free mass.  Typically, when clonidine is administered as an nti-hypertensive, a 
low dose is initially administered and adjusted upwards until the desired response is achieved.  
However, this is rather impractical for our current experiment due to the short duration of 
clonidine administration.  Regardless, differences in body mass, body composition, and 
transdermal absorption may contribute to variability in our outcome variables.    
 In regards to our hypoxic stimulus, we utilized normobaric hypoxia.  For this, we had 
subjects breathe either a 21% or 11% dry gas oxygen mixture, from a mask attached to a non-
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diffusing gas bag that was not humidified.  This is in contrast to hypobaric hypoxia or altitude 
exposure, where there are differences in barometric pressure and the air is often humidified.  
Despite these disparities, we expect there to be minimal difference betw en the varying forms of 
hypoxic stimuli.  Specifically, it has been shown that normobaric hypoxia3, hypobaric hypoxia15, 
and altitude exposure16 are each able to induce insulin resistance. 
 In spite of these limitations, which can be addressed in future studies, our data has sever l 
important clinical implications.  The diseases OSA and COPD are two clinical conditions that 
are characterized by hypoxia and elevated sympathetic activity23,185 and have a high prevalence 
of insulin resistance and impaired glucose tolerance24,25,199,200, independent of other factors such 
as age, sex, and body mass24.  Currently, the most common treatments for OSA and COPD 
include: CPAP and administration of supplemental oxygen.  CPAP is an effective OSA treatment 
as it eliminates bouts of intermittent hypoxia191, decreases sympathetic activity192-194, and  
improves insulin sensitivity29,175.  Supplemental oxygen administration in COPD patients has 
also been shown to positively alter autonomic activity30 and improve insulin sensitivity220.  
Further, our data support the hypothesis that hypoxia induced insulin resistance is mediated by 
elevated sympathetic activity.  In addition to CPAP and supplemental oxygen administration, 
clonidine could serve as a potential therapeutic to ameliorate the decline in insul sensitivity 
associated with OSA and COPD.   
 Moreover, there are millions of individuals exposed to acute hypoxia on a regular basis.  
Individuals voluntarily flock to high altitude ski villages or mountain locales to recreate on a 
year-round basis.  Furthermore, in times of conflict, such as the war in Afghanistan, soldiers are 
acutely exposed to altitude extremes that can induce insulin resistance.  Hypoxia induced insulin 
resistance can deplete glycogen stores and limit performance221.   It is of utmost importance for 
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soldiers to perform at maximal capacity under such extremes to ensure their survival.  Therefore, 
our data provide a mechanism that partially explains the decrease in insulin sensitivity at altitude, 
providing a potential target for future interventions aimed at decreasing symptoms of high 




































Table 1.  Physiological characteristics of the research participants (n = 10 men). 
 
Variable Mean ± SE 
Age (years) 23 ± 1 
Height (m) 1.80 ± 0.01 
Body mass (kg) 78.6  ± 2.6 
Body mass index (kg/m2) 24.2 ± 0.8 
Fat mass (kg) 15.2 ± 0.9 
% Body fat 18.5 ± 1.2 
Fat free mass (kg) 59.9 ± 1.7 
Maximal oxygen uptake (ml/kg/min) 46.8 ± 2.5 
Resting heart rate (beats/min) 59 ± 3 
Resting blood pressure (mmHg) 120/72 ± 3/2 
Fasting blood glucose concentration (mg/dl) 81.3 ± 1.3 





















Table 2.  Heart rate and blood pressure data, prior to and during normoxic and hypoxic gas 
breathing, with and without sympathetic inhibition (48-hour transdermal clonidine 
administration).  * Prior to normoxic or hypoxic gas breathing, clonidine decreased resting heart 
rate (P<0.04) and resting systolic blood pressure (P<0.05).  ** During the hypoxic clamp, heart 
rate was higher (P<0.001), compared to the normoxic clamp.  † Clonidine lowered the hypoxic 
clamp induced elevation in heart rate (P=0.006).  ‡ Clonidine lowered diastolic blood pressure 
during the hypoxic and normoxic clamps (P<0.001), compared to non-clonidine administration.   
 
 Normoxia (FIO2 = 0.21) Hypoxia (FIO2 = 0.11) 
 No Clonidine Clonidine No Clonidine Clonidine 
 Prior to During Prior to During Prior to During Prior to During 
HR(beats/min) 59 ± 3 68 ± 2 55 ± 4* 61 ± 3 57 ± 2 84 ± 4** 49 ± 2* 76 ± 3† 
SBP(mmHg) 120 ± 3 124 ± 3 110 ± 3*114 ± 3 123 ± 3 122 ± 2 113 ± 3* 125 ± 9 
DBP(mmHg) 72 ± 2 71 ± 2 67 ± 3 64 ± 3‡ 75 ± 3 68 ± 2 66 ± 2 63 ± 2‡ 
Data are mean ± SE.  “Prior to” data collected before breathing normoxic or hypoxic gas.  
“During” data are averaged values collected throughout the entire euglycemic hyperinsulinemic 






Figure 1. Summary of insulin signal transduction.  Upon activation and autophosphorylation, the 
insulin receptor activates downstream targets including IRS-1 family proteins, Cbl/CAP and 
MAPK.  Activation of these pathways leads to the regulation of glucose metabolism through 
alterations in GLUT 4 translocation, protein synthesis, enzyme activity, and gene expression2.  
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Saltiel and Kahn, 2001 
 
 
Figure 2.  Hypoxia causes insulin resistance by decreasing arterial oxygen saturation.  The 
decrease in arterial oxygen saturation is sensed by the carot
of the branch point of the internal and external carotid arteries.  Activation of the carotid 
chemoreceptor sends sensory afferent signals to the hypothalamus.  The afferent signals are 
processed and efferent SNS activi
adrenal medulla leads to the secretion of epinephrine whereas transduction of the SNS signal to 
skeletal muscle targets leads to norepinephrine spillover.  Epinephrine and norepinephrine have 
high affinity for beta-adrenergic receptors.  Beta




id chemoreceptor located at the base 
ty is transduced along efferent neurons.  Stimulation of the 






Figure 3.   Arterial oxygen saturation (pulse oximetry) prior to (-15 min) and during (0 – 180 
min) normoxia (FIO2=0.21) and hypoxia (FIO2=0.11), with and without sympathetic inhibition 
(48-hour transdermal clonidine), during the euglycemic hyperinsulinemic clamp procedure.  
Hypoxic gas breathing significantly decreased oxyhemoglobin saturation (P<0.01) compared 
with normoxia at all time points. Clonidine had no effect on arterial oxygen saturation (P>0.25).  












Figure 4.  Plasma norepinephrine prior to (-15 min) and during (0 – 180 min) normoxia 
(FIO2=0.21) and hypoxia (FIO2=0.11), with and without sympathetic inhibition (48-hour 
transdermal clonidine), during the euglycemic hyperinsulinemic clamp procedure.  The area 
under the norepinephrine curve (relative to the normoxic response) was increased with hypoxia 
(137±13%; P=0.02); clonidine prevented the hypoxia induced increase (94±14%; P=0.43).  Data: 










Figure 5.  Plasma epinephrine prior to (-15 min) and during (0–180 min) normoxia (FIO2=0.21) 
and hypoxia (FIO2=0.11), with and without sympathetic inhibition (48-hour transdermal 
clonidine), during the euglycemic hyperinsulinemic clamp procedure.  The area und r the 
epinephrine curve (relative to the normoxia response) was significantly increased in hypoxia 
(371±40%; P<0.001).  Clonidine did not affect the hypoxia induced increase in epinephrine 











Figure 6.  The rate of intravenous glucose administration (adjusted for fatree mass and 
circulating insulin concentration) required to maintain blood glucose concentration at 90 mg/dl 
(5 mmol/L) during standardized intravenous insulin administration during normoxia (FIO2=0.21) 
and hypoxia (FIO2=0.11), with and without sympathetic inhibition (48-hour transdermal 
clonidine).  Data: mean ± SE.  * Denotes difference to normoxia without clonidine (P<0.05).  









Figure 7.  Plasma concentrations of insulin prior to (-15 min) and during (0 and 180 min) 
normoxia (FIO2=0.21) and hypoxia (FIO2=0.11), with and without sympathetic inhibition (48-
hour transdermal clonidine), during the euglycemic hyperinsulinemic clamp procedure.  Data: 





Figure 8.  Plasma concentrations of C-peptide prior to (-15 min) and during (0 ad 180 min) 
normoxia (FIO2=0.21) and hypoxia (FIO2=0.11), with and without sympathetic inhibition (48-
hour transdermal clonidine), during the euglycemic hyperinsulinemic clamp procedure.  Data: 




Figure 9.  Plasma concentrations of non-esterified fatty acid (NEFA) prior to (-15 min) and 
during (0 and 180 min) normoxia (FIO2=0.21) and hypoxia (FIO2=0.11), with and without 
sympathetic inhibition (48-hour transdermal clonidine), during the euglycemic hyperinsulinemic 
clamp procedure.  Data: mean ± SE.  P Values reflect interaction between time, FIO2 and 






Figure 10.  Plasma concentrations of pigment epithelium derived factor (PEDF) prior to (-15 
min) and during (0 and 180 min) normoxia (FIO2=0.21) and hypoxia (FIO2=0.11), with and 
without sympathetic inhibition (48-hour transdermal clonidine), during the euglycemic 
hyperinsulinemic clamp procedure.  Data: mean ± SE.  P Values reflect interaction between 





Figure 11.  Plasma concentrations of oxidized low density lipoprotein (oxidized LDL) prior to   
(-15 min) and during (0 and 180 min) normoxia (FIO2=0.21) and hypoxia (FIO2=0.11), with and 
without sympathetic inhibition (48-hour transdermal clonidine), during the euglycemic 
hyperinsulinemic clamp procedure.  Data: mean ± SE.  P Values reflect interaction between 







Figure 12.  Plasma concentrations of tumor necrosis factor alpha (TNFα) prior to (-15 min) and 
during (0 and 180 min) normoxia (FIO2=0.21) and hypoxia (FIO2=0.11), with and without 
sympathetic inhibition (48-hour transdermal clonidine), during the euglycemic hyperinsulinemic 
clamp procedure.  Data: mean ± SE.  P Values reflect interaction between time, FIO2 and 





Figure 13.  Plasma concentrations of adiponectin prior to (-15 min) and during (0 ad 180 min) 
normoxia (FIO2=0.21) and hypoxia (FIO2=0.11), with and without sympathetic inhibition (48-
hour transdermal clonidine), during the euglycemic hyperinsulinemic clamp procedure.  Data: 
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WHY AM I BEING INVITED TO TAKE PART IN THIS RESEARCH?  
You are an adult man or woman aged between 18 and 65 years.  You do not smoke.  You are not 
pregnant.  Your resting heart rate is greater than 40 beats per minute.  You have normal blood 
pressure (< 140/90 mmHg). 
 
WHO IS DOING THE STUDY? 
Christopher Bell, Ph.D., an assistant professor in the Department of Health and Exercise Science 
at Colorado State University will perform this research. A cardiologist, Dr. Dennis Larson, and 
trained graduate and undergraduate students will assist Dr. Bell.   
 
WHAT IS THE PURPOSE OF THIS STUDY? 
When people are exposed to a low-oxygen environment (for example, at high-altitude) their 
ability to control the concentration of sugar (glucose) in their blood is decreased.  On  possible 
reason for this is the increased in the activity of the nervous system.  The purpose of thi  study is 
to see if decreasing the activity of the nervous system can reverse the decrease in the control of 
blood sugar seen in a low oxygen environment. 
 
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT 
LAST? 
All of the procedures (unless otherwise stated) will take place in the Human Performance 
Clinical/Research laboratory (HPCRL) in the Department of Health & Exercise Science (Moby 
Complex).  
This whole research project will take place over a period of approximately one year.  You will be 
asked to be involved for approximately 2 months.  The total time of your participation is 
approximately 18 hours. 
 




After responding to a questionnaire and completing some initial tests you will be asked to visit 
the HPCRL on 4 separate mornings.  During these visits we will measure your ability to control 
blood sugar while you breathe air that contains either the same amount of oxygen as normal 
room air (21%) or air that contains less oxygen (11%).   
 
For 48-hours prior to and during two of these visits you will wear a patch on your shoulder that 
releases a medication into your body.  This medication will decrease the activity of your nervous 
system.  These visits will be performed in a random order.   
 
You will also be asked to make four additional brief visits for blood pressure checks and patch 
collection.  
 
Below is a detailed description of all of the procedures; a member of the research team will fully 
explain each procedure and its duration. 
 
Screening Visit – 2 Hours 
The first visit to the HPCRL will be a screening visit.  During this visit we will make sure that 
participation in this study is right for you. 
This visit will include the following procedures: 
 
Medical Questionnaire 
You will be asked to answer several pages of questions related to your health, any illness you 
may have or have had, and medications you use or have used in the past.  
 
Pregnancy Test  
If you are female you will be required to have a sample of your urine tested for the p esence of 
human chronic gonadotropin (HCG), a hormone that indicates whether you may be pregnant.  
This will require approximately 1 cup of your urine. If you are pregnant or the test indicates that 
you are pregnant you will not be able to participate in this study.  
 
Blood Pressure 
We will measure your blood pressure using a standard blood pressure cuff (the same as in a 
doctor's office). Blood pressure will be measured during all of the tests perform d in the lab with 
the exception of body composition.  There are no known risks associated with this procedure. 
 
Body Composition 
We will measure how much fat you have in your body using a test called dual energy x-ray 
absorptiometry (DEXA).  The DEXA test requires you to lie quietly on a padded table while a 
small probe gives off low-level x-rays and sends them over your entire body.  This test gives 
very accurate measurements of your body fat and bone mineral density.  We will also measure 
the circumference of your waist and hip using a tape measure.  
 
Exercise Stress Test 
You will be asked to perform a vigorous exercise test.  This test will tell us if your heart is 
healthy.  You will be asked to walk on a motorized treadmill or ride an exercise cy le ( ycle 
ergometer) for approximately 10-15 minutes. The exercise will become more difficult every 2 
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minutes.  While you are walking/riding we will measure your heart rate with an 
electrocardiogram (ECG) and your blood pressure with a cuff placed around your upper arm.  
We will also ask you to wear a nose clip (something that stops you breathing through your nose) 
and ask you to breathe through a mouthpiece.  This will let us measure the gases you brathe.
Depending on your age, a physician may supervise the test.  If we do not think your heart is
healthy you will be referred to your primary care physician for further esting.  There is a chance 
that you may not be allowed to take part in our study. 
 
Remaining Visits 
You will be asked to complete four more long visits and four very quick visits.  Each of the big 
visits will last approximately 4 hours.  The quick visits will last ~ 5 minutes.  During the big 
visits we will measure your ability to control your blood sugar. 
 
Blood Sugar Tests 
This procedure is formally known as the hyperinsulinemic euglycemic clamp and often 
shortened to “The Clamp”.  This procedure measures the ability of your body to contrl sugar.  
This test will take place early in the morning after a 12-hour fast, and abstention from alcohol, 
caffeine and exercise.  We will inject sugar (glucose) and insulin (a naturally occurring substance 
produced by your body) into one of your veins.  From another vein we will sample a very small 
amount of blood (~ 1 ml or 0.2 teaspoons) every 5-minutes for three hours (total amount of blood 
sampled ~ 36 ml or 7.3 teaspoons).  We will measure the amount of sugar in each of these blood 
samples.  We will continue to inject insulin and sugar into your veins to try to keep the 
concentration of sugar in your blood the same.  In order to prepare for the blood sugar tests, you 
will be asked to refrain from exercising for 48 hours, and avoid alcohol and caffeine for 12 
hours.  The night before the blood sugar test you will be asked to eat a standardized meal (a high-
energy drink (e.g. Ensure) and a high-energy snack (e.g. Powerbar)). 
 
Breathing Special Air 
During each of the blood sugar tests you will wear a facemask.  This facemask will be connected 
to a tube.  The tube will be connected to a large balloon.  The balloon will be filled with special 
air from a gas tank.  On two visits the air will contain the same amount of oxygen as normal 
room air (~21%).  On the other two visits the air will contain less oxygen than normal rom air 
(~11%).  You will start breathing from the balloon 15 minutes before the beginning of the blood 
sugar test, and keep breathing from the balloon throughout the remainder of the blood sugar test.     
 
Decreasing The Activity of Your Nervous System 
For two days prior to-, and during two of the blood sugar tests you will wear a clonidine patch.  
Clonidine is a medication used to treat people with high blood pressure.  You will be asked to 
wear a patch on your arm/shoulder that allows clonidine to slowly leak from the patch, through 
your skin and into your blood.  After wearing the clonidine patch for a day, you will be asked to 
visit the HPCRL so that we can measure your blood pressure.  This blood pressure visit will la t 
~ 5 minutes. 
ARE THERE REASONS WHY I SHOULD NOT TAKE PART IN THIS STUDY? You 





1) You are pregnant. 
2) You are a nursing mother. 
3) You suffer from a disease of the cardiovascular or pulmonary systems 
4) You currently use tobacco or have used it regularly within the previous two years. 
5) Your fasting blood glucose concentration is greater than 100 mg/dL (we will measure this for 
you). 
6) You regularly use any prescription medications other than birth control. 
7) You have asthma or any other type of lung/respiratory dysfunction. 
8) Your resting oxygen saturation < 95% (we will measure this for you). 
9) You are unwilling to abstain from exercise for 48 hours prior to testing. 
10) You use anticoagulant therapy or have a known or suspected bleeding disorder. 
11) A contraindication was identified during the screening visit (e.g. positive stress test). 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?  
It is not possible to identify all potential risks in research procedures, but the researcher(s) have 
taken reasonable safeguards to minimize any known and potential, but unknown, risks. The 
Human Performance Clinical Research Laboratory has emergency supplies including a medicine 
trolley equipped with heart machines and supplemental oxygen.  The investigator has a gre t deal 
of experience with all of the procedures.  Some of the procedures for which you are being asked 
to volunteer have a number of associated risks: 
 
Body Composition 
The risks associated with the DEXA are very low.  The maximum radiation dose you will 
receive in this study is less than 1/3000th of the federal and state occupational whole body dose 
limit allowed to radiation workers.  Put another way, you will receive less than 1.3 mrem from 
this scan and you already receive approximately 450 mrem /year from normal background 
radiation dose in Colorado.  The more radiation you receive over the course of your lie, the 
more the risk increases of developing a fatal cancer or inducing changes in genes.  The radiation 
dose you receive from this scan is not expected to significantly increase these risks, but the exact 
increase in such risks is not known.  There are no discomforts associated with this procedure. 
Women who are or could be pregnant should receive no unnecessary radiation and should not 
participate in this study. 
Exercise Tests 
There is a very small chance of an irregular heartbeat during exercise (< 1% of all subjects).  
Other rare risks of a stress test are heart attack (< 5 in 10,000) and death (<2 in 10,000).  
Wearing a mouthpiece and nose-clip can sometimes cause dryness in the mouth and mild
discomfort.  
Blood Collection 
When the needle goes into a vein, it may hurt for a short period of time (a few seconds).  Also 
there may be minor discomfort of having the needle/plastic tube taped to your arm.  In about 1 in 
10 cases, a small amount of bleeding will occur under the skin that will cause a bruise.  The risk 
of forming a blood clot in the vein is about 1 in 100, and the risk of significant blood loss is 1 in 
1,000.  Additionally, there is a risk that you may faint while having blood collected or having the 




Blood Sugar Test 
The procedure involves placement of a catheter (hollow plastic needle) inside a vein thus the 
usual risks of blood collection apply (minor discomfort, bruising, fainting and blood clot (rare)).  
In addition there is a risk of hypoglycemia (low blood sugar); symptoms include hung r, 
nervousness and shakiness, perspiration, dizziness or light-headedness, sleepiness, confusion, 
difficulty speaking, and feeling anxious or weak.  Although hypoglycemia can happen suddenly 
it can usually be treated very quickly by terminating the insulin infusion and continuing the 
glucose infusion, returning blood sugar concentration back to normal.  To reduce the risk of 
hypoglycemia, blood glucose concentration is measured every 5 minutes.  If blood gluc se 
concentration falls below 65 mg/dL insulin administration will be terminated and glucose 
infusion continued until normal concentration (70 – 100 mg/dL) is resumed; this usually occurs
very quickly (~ 5 minutes). 
  
Breathing Special Air Containing Less Oxygen Than Normal Room Air 
The risks associated with breathing a gas that contains less oxygen than normal ro m ir include 
nervousness and shakiness, perspiration, dizziness or light-headedness, sleepiness, confusion, 
difficulty speaking, and feeling anxious or weak.  We will measure your heart rate, oxygen 
saturation (how oxygen you have in your blood), and blood pressure; if oxygen saturation falls 
below 70%, heart rate increases by more than 50 beats per minute above rest, or blood pressure 
increases by more than 35 mmHg above rest, the test will be terminated. Should you decide you 
no longer wish to continue breathing the special air, the facemask is very easy to remove.  
Supplemental air (100% oxygen) will be available on request or if needed.  Symptoms associated 
with low oxygen can be treated very, very quickly by breathing normal room air and/or 
supplemental oxygen.  
 
Decreasing The Activity of Your Nervous System 
We will be giving you a similar amount of clonidine that is usually given to people with high 
blood pressure.  This drug will lower your heart rate and blood pressure. There is a small risk of 
hypotension (low blood pressure).  The symptoms of blood pressure dropping too low are 
dizziness, fainting, or in rare instances heart block.  If your mean blood pressure falls b low 90 
mmHg, or if your heart rate falls below 40 beats per minute we will stop giving you the 
clonidine.  There is also a small risk of dry mouth, tiredness or weakness, and irritation ( chy 
skin) at place where you wear the patch.  To help avoid any unpleasant side effects we will be 
taking a number of precautions: 
1) We measure your heart rate and blood pressure after 1 day of wearing the clonidine patch. 
2) You will be given a list of people and their telephone numbers who you should contact if you 
feel unwell while you are wearing the patch. 
3) You will be given a credit card sized laminated tag to carry while you are wearing the patch.  
The tag will read, “Clonidine Alert.  I am a participant in a clinical research investigation.  I 
currently receive 0.2 mg of transdermal clonidine per day.  For information please call Dr. 






ARE THERE ANY BENEFITS FROM TAKING PART IN THIS STUDY?  
There are no direct benefits in participating, however you will receive a copy of your results and 
information pertinent to your body composition (i.e. height and weight), and metabolic and 
cardiovascular risk factors.  For example, in blood we will measure concentrations of nsulin and 
glucose.  You will be provided with a copy of your DEXA scan; you may wish to have this 
interpreted by a medically qualified professional. Finally, this study has the potential to identify a 
physiological mechanism of high-altitude induced insulin resistance, and subsequently provide a 
practical pharmacological intervention.  
  
DO I HAVE TO TAKE PART IN THE STUDY? 
Your participation in this research is voluntary. If you decide to participate n the study, you may 
withdraw your consent and stop participating at any time without penalty or loss of benefits to 
which you are otherwise entitled.   
WHAT WILL IT COST ME TO PARTICIPATE?  
Other than transport to and from the lab, your participation should incur no costs. 
 
WHO WILL SEE THE INFORMATION THAT I GIVE?  
We will keep private all research records that identify you, to the extent allowed by law. 
 
Your information will be combined with information from other people taking part in the study. 
When we write about the study to share it with other researchers, we will write about the 
combined information we have gathered. You will not be identified in these written matrials. 
We may publish the results of this study; however, we will keep your name and other identify ng 
information private.  
 
Your identity/record of receiving compensation (NOT your data) may be made available to CSU 
officials for financial audits. 
CAN MY TAKING PART IN THE STUDY END EARLY?  
Your participation in the study could end if you become pregnant, or if you miss any ofthe 
scheduled appointments.   
 
WILL I RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY ? On 
completion of the study you will receive $300.  Should your participation in the study end early, 
you will still receive feedback pertaining to your health and fitness.   
 
WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH? The Colorado 
Governmental Immunity Act determines and may limit Colorado State University's legal 
responsibility if an injury happens because of this study. Claims against the University must be 
filed within 180 days of the injury. 
WHAT IF I HAVE QUESTIONS?       
Before you decide whether to accept this invitation to take part in the study, please ask any 
questions that might come to mind now.  Later, if you have questions about the study, you can 
contact the investigator, Christopher Bell at physiology@cahs.colostate.edu or 970-491-3495. If 
you have any questions about your rights as a volunteer in this research, contact Janell Barker, 
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Human Research Administrator at 970-491-1655.  We will give you a copy of this consent form 
to take with you. 
 
This consent form was approved by the CSU Institutional Review Board for the protection of 
human subjects in research on (Approval Date). 
 
WHAT ELSE DO I NEED TO KNOW?  
Your signature acknowledges that you have read the information stated and willigly sign this 
consent form.  Your signature also acknowledges that you have received, on the date signed, a 













_______________________________________  _____________________ 




_________________________________________    
Signature of Research Staff   
 
 
 
 
 
 
 
